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Abstract
Controlled-release tablets enhance the effectiveness of therapies for various clinical
conditions. Photocrosslinkable polyanhydrides that undergo surface erosion were recently
introduced as suitable materials for manufacturing tablets with tunable release profiles.
However, their erosion behavior has not been comprehensively studied. In this thesis, the
erosion kinetics of photocrosslinkable polyanhydrides was studied by exploring the impact of
different parameters (the polymer composition and geometry, as well as the temperature, pH,
and shaking rate of the solution during the in vitro experiments) on their mass loss profiles,
followed by a release kinetic model fitting. The results indicate that the temperature was the
only parameter that could affect the induction period (the lag time) substantially. Moreover,
polymers with the same surface area to volume ratios showed similar mass loss percentage
despite their dissimilar volumes and surface areas. Although tablets with adjustable release
profiles have been studied before, lack of a fast and large-scale production technique is a
significant limitation that holds back their widespread application. A high-throughput
fabrication platform was developed that was then utilized to manufacture controlled-release
polyanhydride tablets. Tunable release profiles with the high-throughput fabricated tablets
were achieved.

Keywords
Controlled-release drug delivery system, surface erosion, polyanhydrides, erosion kinetic,
drug-loaded tablets, adjustable release profiles, high-throughput fabrication.
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Summary for Lay Audience
Oral drug delivery is the preferred route for medication administration due to its lower cost
and higher convenience for patients compared to other methods such as injection and
implantation. The conventional form of oral tablets, however, requires multiple
administrations to maintain the concentration of drugs in the bloodstream at an effective
level. Controlled-release tablets have emerged as an alternative that can sustain the drug
dosage at an effective level for a long period of time, aiming at enhancing the effectiveness
of therapies in various clinical conditions. In addition, tablets with adjustable release profiles
of the drug have been explored to improve the treatment efficacy for diseases that require
different temporal profiles of the drug concentration. These tablets are typically made of a
special class of polymers called biodegradable polymers, meaning that they are safely
decomposed by the human body after they release the drug.
Polyanhydride is a biodegradable polymer that is considered as an appropriate option for
being used in the fabrication of tablets with adjustable release profiles. Polyanhydrides are
mostly eroded from their surfaces at predictable rates when they are exposed to the aqueous
media. Understanding the erosion behavior (and hence the mass loss profile) of a newly
introduced type of polyanhydride is an essential step before its utilization in fabricating
tablets with adjustable release profiles. In this thesis, we first studied the erosion behavior of
the new type of polyanhydride by exploring the impact of different parameters on their mass
loss profiles. Moreover, we fitted the experimental mass loss data to different release kinetic
models to gain a better understanding of the erosion behavior.
Although tablets with adjustable release profiles have been around for a while, lack of a fast
and large-scale production technique has remained an important limitation that holds back
their widespread application. We developed a high-throughput fabrication platform that we
then utilized to manufacture polyanhydride tablets with controllable release profiles. We
achieved tunable release profiles with the high-throughput fabricated tablets. Finally, we
increased the capacity of the tablets for drug loading by implementing and fabricating
modified tablet designs.
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Chapter 1

1

Introduction

This chapter provides an overall introduction to the thesis work.

1.1

Overview

Oral drug delivery systems (DDSs) comprise more than 50% of the drug delivery market.
Patients prefer the oral route for drug administration because it is economical,
noninvasive, and does not require expertise for administration1,2. Conventional means of
oral DDSs release the entire therapeutic substance immediately after administration. This
leads to an instant increase, followed by a rapid decrease (to a sub-therapeutic level) in
the drug concentration in the bloodstream. Therefore, to keep the drug concentration at
therapeutic levels, multiple administrations at regular intervals are required.
Controlled release systems (CRSs) have emerged to enhance the patients' compliance and
convenience by improving drugs’ efficacy, reducing the chances of drug toxicity, and
eliminating the need for multiple administrations3. Biodegradables polymers have been
widely used in controlled DDSs because of their tunable mechanical properties. Synthetic
biodegradable polymers, in particular, are of interest due to their unlimited availability4.
A biodegradable polymer undergoes mass loss either by bulk erosion or by surface
erosion. Most of the biodegradable polymers used in CRSs, e.g. polyesters, undergo bulk
erosion. Bulk-erodible polymers erode from their interior and exterior simultaneously,
resulting in low predictability of the drug release kinetics from these polymers. In
contrast, surface-erodible polymers lose the polymer moieties from their surface, and
therefore their initial geometry is preserved while the size of the polymer decreases.
Besides, the mechanical properties of the surface-erodible polymers do not change during
the erosion. The highly reproducible and predictable release kinetics of the surface
eroding polymers make them desirable options in manufacturing the controlled DDSs3.
Polyanhydrides predominantly undergo surface erosion because of their hydrophobic
backbone and hydrolytically unstable anhydride bonds. Polyanhydrides have been shown
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to maintain their surface eroding behavior at sizes as small as 100 𝜇m, that is the smallest
value reported for surface eroding polymers5. Unlike other surface-erodible polymers
such as polyorthoesters (POEs) that undergo surface erosion only in acidic environments,
polyanhydrides have shown surface erosion in acidic, alkaline, and neutral
environments6. Despite their attractive properties for controlled DDSs7, polyanhydrides
have not been used as often compared to other biodegradable polymers such as
polyesters. This can be attributed to the difficulties involved in their synthesis. In 2009, a
new photocrosslinkable polyanhydride using thiol-ene polymerization was reporeted8.
The polymerization process was straightforward and fast compared to other processes
used for polyanhydrides synthesis.
Fully characterization of the new type of polyanhydrides, as well as investigating the
impact of different parameters on its erosion behavior are essential before its utilization
in controlled DDSs. There exist some parameters that may substantially affect the erosion
of thiol-ene polyanhydrides, but have not yet been studied. For example, the polymer
composition, temperature, pH of the media, the geometry of the polymers, and the media
shaking rate (the convective force for the polymer erosion). The first objective of this
study is to explore the erosion behavior of this type of polyanhydrides and gain a better
understanding of their mass loss profiles. We then use these polymers for fabricating
tablets with a new design proposed in this study (see below).
Controlling the temporal profile of drug release is vital for achieving the optimal
therapeutic effect. Despite the substantial progress in developing controlled-release
tablets, most of the existing designs only offer monotonic, or sustained release profiles.
However, different types of clinical circumstances necessitate different types of release
profiles for optimal treatment. The temporal patterns are mostly defined by the effect of
the circadian rhythm on different clinical circumstances, giving rise to specific rhythms
of medical conditions during the 24 hours of the day. Besides, various factors such as the
patient’s condition, age, and gender call for patient-specific treatments via personalized
medicine. The increased awareness of individualized therapy and introduction of various
biodegradable polymers with adjustable physicochemical properties encourage the
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development of fabrication methods for manufacturing advanced controlled DDSs that
enable releasing of drugs at controllable rates.
The traditional compression tableting that is used by pharmaceutical industries for
manufacturing tablets and capsules9 does not provide the flexibility required for
fabricating controlled DDSs. Micro-fabrication has been used in some studies owing to
its ability to manufacture tiny features while providing control over the shape or
geometry of the delivery devices. The combination of micro-fabrication techniques such
as standard photolithography, with repeated replica molding steps, has been reported that
allows for easy, rapid, and precise manufacturing of drug delivery devices at relatively
low costs10,11. This method has been used to fabricate microchips as CRSs that generate
long-term pulsatile release12. Although the micro-fabrication methods provide a high
resolution and have the potential for high-throughput manufacturing, the limitations
associated with using implantable microchips have left the oral controlled DDSs the
preferred option13,1. 3D printing is another technology that has been studied extensively
by researchers for fabricating polymeric oral tablets with adjustable release profiles14.
Most of the studies fabricated tablets with monotonic or constant release profiles of
drugs, with some reporting more complicated (e.g. pulsatile) release profiles. The
complicated release patterns were achieved by elaborate tablet designs and specific
fabrication techniques, demonstrating the feasibility of creating tablets with various
release patterns of drugs.
Although these studies show that the fabrication of personalized tablets is no longer an
issue, there exist some limitations in the current fabrication methods used for modifiedrelease tablets that can hinder their widespread application. Some of these limitations can
be addressed by improving the tablet design and/or the appropriate choice of the
fabrication method. As an example for the latter, the resolution of the fabrication method
is an important parameter that can determine the precision of the release rate. The
inexpensive and commercially available 3D printers have relatively low resolution, while
higher resolution 3D printers are limited by their small range of resins (printable
materials). On the other hand, micro-fabrication techniques such as photolithography are
capable of creating miniaturized features with high resolution. Besides resolution,
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scalability and high-throughput manufacturing is a critical characteristic of any
potentially successful fabrication method. High-throughput manufacturing is currently a
challenge for producing advanced controlled DDSs with adjustable release rates. Most of
the studies reported the fabrication of a single tablet in each experiment, reducing the
chances of their practical use in clinical settings. Manufacturing each tablet can take
considerable amount of time, and the reproducibility level is low.
The second objective of this study is to use the thiol-ene polyanhydrides that we
characterized during the first step for high-throughput fabrication of tablets with the new
design proposed in this thesis. We aim at addressing the challenges in the fabrication of
controlled-release tablets with adjustable release profiles of drugs by developing a highthroughput fabrication platform that manufactures tablets with high resolutions.

1.2

Thesis Outline

This thesis is divided into five chapters. A brief introduction and the motivation for this
research are included in Chapter 1.
The relevant background information on the role of biodegradable polymers in controlled
DDSs, the importance of polyanhydrides as surface eroding polymers, parameters
affecting the erosion of polyanhydrides, the need for different release profiles of drugs,
and the key concepts of advanced fabrication methods for manufacturing CRSs with
adjustable release profiles is provided in Chapter 2. A broad literature review on the
current research and challenges of obtaining erosion kinetics of thiol-ene polyanhydrides
is also presented in Chapter 2. Lastly, the advances in controlled DDS fabrication
methods are discussed focusing on micro-technology and 3D printing methods.
The main research findings are presented in chapters 3 and 4. Chapter 3 reports a
comprehensive study on the mass loss profile of thiol-ene polyanhydrides. This chapter
details the materials used in the mass loss experiments followed by the methodology of
polymer preparation and characterization, experimental designs to explore the effect of
different parameters on mass loss of the thiol-ene polyanhydrides, and the theoretical
concepts for release kinetic model fitting. The results of the effects of parameters on mass
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loss (erosion) profiles of polyanhydrides synthesized by thiol-ene photopolymerization
are discussed. A comparative study on the release kinetic models and their fitting to the
experimental data is carried out for a better understanding of polymers’ erosion behavior.
Chapter 4 reports the high-throughput fabrication of tablets that are designed using a new
approach, enabling adjustable drug release rates. The methodology of developing a highthroughput platform using a combination of micro-fabrication and 3D printing
technology for rapid manufacturing of the erodible tablets is provided in this chapter.
Several experiments were conducted with various tablet designs, and the results show the
different release profiles obtained from these tablets.
Chapter 5 summarizes and concludes the results of chapters 3 and 4 and provides
directions for future work.
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Chapter 2
Background and Literature Review

2

This chapter provides the relevant background information on the emergence of
controlled release technology, the role of biodegradable polymers in controlled release
DDSs, and highlights the importance of polyanhydrides, as surface eroding polymers, in
achieving desired release rates required in personalized medicine. Parameters affecting
the erosion behavior of polyanhydrides and studies on these parameters is discussed.
Lastly, this chapter discusses recent developments in fabrication methods of polymeric
DDSs with controllable release profiles of drugs; focusing on using micro-technology
and 3D printing for oral dosage forms.

2.1

Polymeric Controlled Drug Delivery Systems

This section describes the conventional DDSs and discusses the need for CRSs.

2.1.1

Conventional Drug Delivery Systems

The oral dosage is the most common route for the delivery of therapeutic agents,
constituting about 40% of the drug administrations1. When administered orally,
therapeutics are safely taken by patients without the assistance of a healthcare
professional. In comparison to injection administration routes (e.g., subcutaneous,
intramuscular, intravenous), oral delivery has minimal discomfort. These advantages of
oral drug delivery over other drug administration routes, as well as the ease of the drug
administration and the high level of patients’ convenience, have resulted in the allocation
of more than 50% of the drug delivery market to oral DDSs2,3.
Conventional means of oral DDSs release therapeutic substances all at once (immediaterelease) resulting in a sudden increase of drug concentration followed by a rapid decrease
to a lower than effective level of drug in the bloodstream. In such settings, the duration in
which the plasma concentration is effective without being tioxic is short, rendering the
conventional release systems suboptimal. Figure 2-1 shows the importance of keeping the
drug concentration level in the therapeutic window (below the toxic and above the sub-
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therapeutic level). This figure also displays multiple administrations required for drugs to
maintain their concentration within the therapeutic window. The multiple administrations
reduce the patients’ compliance and cause fluctuations in the drug dose level in the blood.

Figure 2-1: Drug plasma concentration in conventional DDSs that requires multiple drug
administrations to keep the concentration of the drug in the therapeutic window.

2.1.2

Emergence of Controlled Release Technology

Controlled DDSs have emerged to improve patients’ health by improving the drug
efficacy, reducing the dose-dependent drug toxicity, and enhancing patient compliance
and convenience. The tunable release of therapeutic substances in response to time or
different stimuli (temperature, pH, enzymes, etc.), while maintaining the dose at the
effective level, is called controlled release drug delivery4. Maintaining the level of the
biologically active agents in the effective zone decreases the chances of drug toxicity, and
hence the side effects. Controlled DDSs are designed to sustain the required plasma
dosage for an extended period of time and consequently eliminate the need for frequent
administrations. Figure 2-2 compares the burst release of a drug through the conventional
means of delivery with drug release from a controlled DDS. Figure 2-2 also shows an
example of a pulsatile release as an example of a physiologically required release profile
that can be achieved by designing more complicated controlled DDSs5.
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Controlled DDSs often utilize synthetic biodegradable polymers to act as carriers for
delivering their cargos. Several biodegradables polymers have been widely used to create
the controlled DDSs. Based on the site of action and the desired temporal release profile,
polymers with specific physicochemical properties can be utilized6.

Figure 2-2: Comparison of the conventional DDSs’ burst release with sustained-release
obtained by a controlled DDS. The pulsatile release is one of the critical physiologically required
release pattern, which is achievable using controlled DDSs. Reproduced from Ref

5

with

permission.

2.1.2.1

Biodegradable Polymers in Controlled DDSs

Biodegradable polymers have been widely used in drug delivery applications because of
their advantages over other materials, specifically their adjustable mechanical properties
as an important factor for achieving more efficient DDSs. In the past 50 years, synthetic
biodegradable polymers have been preferred over the naturally occurring ones for the use
in advanced delivery systems due to their availability and their easily adjustable
physicochemical properties7. In the 1960s, polyesters such as poly(D,L-lactic acid)
(PLA), poly(glycolic acid) (PGA), and their copolymer poly(D,L-lactic-co-glycolic acid)
(PLGA) were developed as synthetic biodegradable polymeric sutures 8. Since then,
synthetic biodegradable polymers have been extensively used as biocompatible delivery
systems that are easily eliminated after the therapeutic is released in the human body.
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Aliphatic polyesters such as PLA, PGA, and polycaprolactone (PCL), among
biodegradable polymers, are the most frequently used materials in biomedical
applications owing to their availability, biocompatibility, and flexible degradability9.
These polyesters, as well as other synthetic biodegradable polymers, including
polyphosphazenes, polyurethanes, polyanhydrides, and POEs, have been extensively
studied over the past 20 years for advanced DDSs applications9–11.

2.1.3

Controlled Drug Release Mechanisms

A variety of available drugs in the market for the treatment of different diseases increases
the importance of using CRSs to elevate the efficacy of those drugs. The primary role of
CRSs is releasing drugs for an extended period (days to weeks) at a controllable rate. A
significant number of CRSs have been developed for various clinical conditions.
Choosing the most suitable delivery system required for a specific clinical condition
requires knowledge about different mechanisms of CRSs as well as their systems design
factors4.
CRSs utilizing polymers as carriers are divided into five main categories: diffusion and
dissolution, solvent activated (swelling and osmotic-controlled), ion-exchange, stimuliresponsive, and chemically mediated (erosion and degradation controlled) systems4,12.
These categories and the mechanisms by which they control the drug release will be
briefly discussed in this chapter with the focus being on the chemically-controlled
mechanisms, which are employed in this study.

2.1.3.1

Diffusion and Dissolution CRSs

Diffusion release is the most common mechanism of releasing drugs from polymers12.
The migration of compounds from their initial point to the lower concentration area in the
polymer is called a diffusion release mechanism. Diffusion CRSs are designed as
reservoir systems or polymeric matrix systems. Reservoir systems typically consist of a
water-insoluble polymeric membrane through which the drug diffuses out while in
polymeric matrix systems, the drug is released by passing through the matrix itself.
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As shown in Figure 2-3A, in both reservoir systems and polymeric matrices the drug can
be dissolved in aqueous solution either above the saturation concentrations (constant drug
source reservoir and monolithic dispersion matrices) or below the saturation level (nonconstant drug source reservoir and monolithic solution matrices). In the former case, the
concentration of the drug inside the polymer decreases over time by releasing the
dissolved drug. Therefore, undissolved drug aggregates will be dissolved in order to
replace the released drug, which leads to a controlled release rate (almost zero-order
release). When the drug aggregates have fully dissolved, the concentration of the drug in
the polymer goes under the saturation level. From this step onward, the constant drug
source reservoir and monolithic dispersion matrices behave similarly to non-constant
drug source reservoir and monolithic solution matrices, respectively, where the amount of
the drug-releasing out of the polymer decreases over time until the completion of the drug
release4, as shown in Figure 2-3A.
Dissolution CRSs can also be designed as reservoirs or matrix systems (Figure 2-3B).
Slowly dissolving polymers coat drugs in reservoir systems and the dissolution rate of the
polymer defines the release rate of drugs. In dissolution-controlled matrix systems, drugs
are encapsulated within a polymer and are released while the matrix is dissolving.
Therefore, one of the essential factors for selecting the suitable polymer for a dissolution
CRS is the solubility of the polymer that affects the release rate of the loaded drug13.
Most of CRSs are a combination of the diffusion and dissolution systems in which drugs
are trapped in polymeric membranes or matrices. Due to polymer dissolution, some pores
will be created that allow water penetration to the polymer. As a result of the water flow
inside the polymeric structure, the drug diffuses out of the polymeric matrices or
membranes. Sometimes one of these mechanisms dominates the other that results in
dissolution-limited or diffusion-limited CRSs14.
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Figure 2-3: Schematic illustration of A) Diffusion CRSs. Drugs are trapped in systems at time t 0
and diffuse out through the reservoir systems or polymeric matrices at time t 1 and t2. In nonconstant drug source reservoirs or monolithic solution systems, the concentration of the drug
reduces over time while the drug release can be controlled for a prolonged time in constant drug
source reservoir or monolithic dispersion systems. B) Dissolution CRSs. In reservoir systems, the
thickness of the membrane determines the drug release rate by controlling the dissolution rate of
the polymer. In matrix systems, the dissolution of the boundary layer determines the release rate
of the drug. Reproduced from Ref 4 with permission.
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2.1.3.2

Solvent-activated CRSs

The penetration of water or body fluids into some polymeric systems causes the
controlled release of drugs. Solvent-activated systems can be divided into swellingcontrolled and osmotic pressure-controlled systems12.
Semipermeable polymeric membranes which are permeable to water and impermeable to
drugs produce osmotic pressure in osmotic pressure-controlled systems. There are small
holes (orifices) on these membranes, acting as pathways for drugs to be released. Figure
2-4A shows two types of osmotic CRSs: 1) the drugs are loaded in the osmotic core (type
A) or 2) the drugs are trapped in the reservoir surrounded by the osmotic core (type B).
The osmotic pressure caused by the water permeation into the polymeric membrane
through the orifices is the driving force of the drug release. Permeability of the polymeric
membrane, the size of orifices, and the level of osmotic pressure control the release of the
biologically activated agents4,14,15.
In swelling-controlled systems, polymers such as natural or synthetic hydrogels are used
that can absorb a considerable amount of water after being immersed in water. When
these polymers swell in the presence of water or body fluids, their volume increases and
the contents of the solvent come out from the polymer (Figure 2-4B). Diffusion of the
drug through the polymer and the swelling characteristic of the polymer control the drug
release rate4,15.

2.1.3.3

Stimuli-responsive and Ion-exchange CRSs

Some of the polymeric carriers can be activated to release their cargo by external stimuli
including physical, chemical, magnetic, electrical, or mechanical stimuli that create cues
for polymers with specific properties to be activated. These structures can be used for
both targeted drug delivery and temporal CRSs. Several studies have been conducted on
thermo-responsive, light-responsive, redox-responsive, pH-responsive, and enzymeresponsive controlled release DDSs9. Figure 2-4C displays how physical stimuli can
activate some responsive polymers to release their therapeutics.
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Figure 2-4: Schematic illustration of A) Osmotic-controlled systems. Reproduced from Ref

4

with permission. B) The swelling-controlled system. C) External physical stimuli to activate the
responsive polymeric carriers to release their cargo in a controllable manner. Reproduced from
Ref 9 with permission.

Ion-exchange CRSs typically consist of resins made of cross-linked polymers with a
considerable number of anionic and cationic functional groups. Body fluids can flow into
their structure because of the cross-linked backbone of the polymer, and at the same time,
the ionic part of the structure enables the ionic groups to exchange their mobile ions with
another cation or anion16. Therefore, there are two types of ionic exchange DDSs: the
release of cationic drugs using anionic resins, or release of anionic drugs using cationic

15

resins. Ionic strength, pH of the human body environment, and cross-link density of the
resin can control the drug release rate4.

2.1.3.4

Chemically-mediated CRSs

Chemical reactions also play an integral role in controlling the release rate of drugs using
polymeric systems. Chemically-controlled systems are generally divided into two groups:
the pendant chain, and erosion-controlled systems. In pendant side chain systems, drugs
are covalently linked to the polymer backbone with the polymers degrading once exposed
to body fluids or water. The targeted site for delivering the drug has its own
characteristics, which may lead to hydrolytic or enzymatic degradation of bonds between
the drug and the polymer (Figure 2-5A). These systems can be used for targeted drug
delivery. The rate of the hydrolysis and the enzymatic degradation rate of the drugpolymer conjugation determines the rate by which the drugs detach from the polymer
backbone4.
In erodible controlled release polymeric systems, drugs are dispersed in a matrix and will
be released upon degradation of the erodible polymer (Figure 2-5B). If the drug diffusion
rate from the polymer is much faster than the erosion rate of the polymeric matrix, the
kinetics of the drug release is diffusion-controlled, which is described in previous
sections. If the diffusion rate of the drug through the polymer is lower than the erosion
rate of the polymeric matrix, it would be erosion-controlled system17.
There are two types of erosion mechanisms, namely bulk and surface erosion. Bulk
eroding polymers are those that degrade from their bulk in contact with water because the
permeation rate of the water molecules into the bulk of the polymer is faster than the
erosion rate of the polymer. Surface eroding polymers are eroded from their surface,
because of their faster erosion rate than the water penetration rate to their polymer bulk.
In surface erosion, polymer moieties are detached from the surface of the polymer such
that the size of the polymer decreases while preserving the initial geometry of the
polymer (Figure 2-5C)6.
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Figure 2-5: Schematic illustration of chemically-controlled release systems. A) Pendant side
chain systems. B) Erosion controlled systems. Reproduced from Ref

4

with permission. C)

Surface erosion versus bulk erosion mechanism.

Although for biodegradable polymers, a combination of both mechanisms occurs
depending on the chemical structure of the polymer backbone, most of the biodegradable
polymers used for CRSs (e.g. famous polyesters) undergo bulk erosion. Since water can
penetrate to the bulk of these polymers, the drug is not sufficiently protected during the
treatment, and the predictability of the drug release kinetics during the bulk erosion is
low. In contrast, surface eroding systems protect the water labile drugs as water cannot
rapidly permeate to the bulk of the polymer. Another exciting characteristic of surface
eroding polymers is their mechanical properties which do not change during erosion.
Besides, the highly reproducible and predictable release kinetics of the surface eroding
systems make them desirable for controlled DDSs6.
Two types of biodegradable polymers predominantly undergo surface erosion: POEs and
polyanhydrides. They both have highly labile functional groups leading to fast hydrolysis
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on the surface, and because of the hydrophobic backbone, water cannot quickly pass
through the bulk of the polymer. The majority of water at the surface of the polymer is
consumed before water can penetrate the polymer bulk. POEs showed surface erosion in
lower PHs conditions (in an acidic environment) while Polyanhydrides showed surface
erosion in acidic, alkaline, and neutral environment which makes the polyanhydrides a
desirable option to be used as a CRS18.
Recent considerable progress in the development of advanced micro- and nano-scale
DDSs has encouraged the use of erodible systems in small scales. The critical device
dimension (Lcritical) is reported as a criterion for determining the type of erosion of a
specific polymer. An erodible matrix with dimensions larger than Lcritical undergoes
surface erosion; otherwise, it undergoes bulk erosion. The estimations of Lcritical for
different polymers are available in the literature. The value of Lcritical for polyanhydrides
was calculated to be 10−4 m, which is the smallest value reported for surface eroding
polymers. It means that polyanhydrides undergo surface erosion down to almost 10-4 m,
allowing for manufacturing erodible CRSs even in microscopic scales 19.

2.2

Polyanhydrides

Although Bucher and Slade had synthesized polyanhydrides for the first time in 1909,
these polymers attracted more attention in the 1980s when Langer used them as
controlled DDSs20. Polyanhydrides rapidly degrade in acidic, alkaline, and a neutral
aqueous environment. In comparison to other hydrolytically degradable bonds such as
amides and esters, anhydride bonds are more unstable and have the shortest average halflife. Furthermore, polyanhydrides predominantly undergo surface erosion because of the
hydrophobic backbone and hydrolytically unstable anhydride bonds in their structure.
Due to the surface erosion mechanism, the release rate of the dispersed drugs in these
polymeric systems ideally follows the erosion rate of the polymer. Because of these
capabilities, they have a high potential to be used as controlled DDSs21.
Despite many interesting properties of polyanhydrides for drug delivery applications,
these polymers have not been used as often compared to other biodegradable polymers
such as polyesters. The only US Food and Drug Administration (FDA)-approved product
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made of polyanhydrides is the Gliadel Wafer (a polyanhydride-based implant for locally
delivering the anticancer agent to a brain tumor)22. Difficulties involved in the synthesis
of polyanhydrides are the main reason for their less popularity compared to other
biodegradable polymers.

2.2.1

Polyanhydrides’ Synthesis Pathways towards Radical
Polymerization

The high reactivity of anhydride functional groups in the vicinity of nucleophilic species,
such as water causes difficulties in the synthesis of polyanhydrides. The most common
pathway of synthesizing polyanhydrides is polycondensation. There are some limitations
for polycondensation methods, including the very high temperature and the low pressure
needed during the synthesis steps23. Domb et al. reported a method to synthesize
polyanhydrides using coupling agents (phosgene and diphosgene) conducted at ambient
temperature and eliminated the need for the purification steps required in
polycondensation24. The limitation of this method is difficulties in removing the solvents
such as toluene.
Photopolymerization of methacrylate anhydride monomers was investigated by Langer
group to achieve more manageable synthesis steps in addition to the capability of in vivo
synthesis. The use of the methacrylate group in this study paved the way for utilizing the
radical polymerization for synthesizing polyanhydrides. The radical polymerization can
be initiated by thermal-, redox- or photo-initiators. Among these radical polymerization
methods, photopolymerization undergoes a faster reaction while having a spatiotemporal
control over the polymer synthesis23. In 2009 Shipp et al.
photocrosslinkable

polyanhydrides

using

thiol-ene
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have synthesized a new

polymerization

under

more

straightforward conditions. Facile synthesis of these polyanhydrides in quite rapid
reactions (around 15 minutes) using commercially available monomers alleviated the
challenges in the synthesis of polyanhydrides reported in previous approaches.
Thiol-ene polymerization, a type of click chemistry polymerization, is another radical
polymerization process that has been used to synthesize polyanhydrides. The click
chemistry is a method through which high yields of chemical species can be synthesized
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in very rapid reactions while the reaction condition is simple26. It allows for the
conversion of almost all monomers to higher molecular weight product in a simple way.
Thiol-ene reactions can occur by the existence of radical initiators (thermal-, redox, or
photo-initiators or a combination of these three). In thiol-ene reactions, the hydrogen
atoms of the thiol moiety are abstracted and produce a thyl radical which is added to the
alkene following an anti-Markonikov rule (Figure 2-6). Photo-crosslinking also allows
for precise control over the polymer formation by directing the light source, and the
reaction is quite rapid so that oxygen atoms do not have the chance to play a role in the
reaction. This process generally takes from a few seconds to a few minutes21.

Figure 2-6: The thiol-ene reaction scheme.

2.2.2

Parameters affecting Polyanhydrides Erosion

A desired erosion-controlled DDS is the one that can complete the drug release at the
same time when erosion is completed. Depending on the ultimate application, this time
can vary from a few hours to weeks or even years. Polyanhydride was used for controlled
DDSs in the early 1980s as an alternative to PLA, and PLGA which can only release
drugs over a few weeks20.
As described in previous sections, biodegradable polymers typically undergo two types of
erosion: bulk and surface erosion. The essential characteristic of polyanhydrides is their
highly unstable anhydride groups in addition to their hydrophobic structure, leading to
almost complete surface erosion. The drug release rate from surface-erodible polymers
such as polyanhydrides is proportional to the external surface area of polymers. Near
zero-order drug release rate (following the polymer linear mass loss kinetic) which is a
desired release rate for the controlled release DDSs is achievable using this class of
polymers27. The most critical measure for polymer erosion is known to be the polymer
mass loss. For example, for a matrix with slab geometry, surface erosion means a linear
mass loss profile28.
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Different properties of polymers, including crystallinity, hydrophobicity, and water
diffusivity, are dictated by polymer composition that affects the polymer erosion
behavior29. By changing the monomers’ initial mole ratios, the degradation rate can be
adjusted while the surface erosion maintains the dominant mode of erosion. Monomers
with different hydrophobicity form polymers with various crystallinity. More crystalline
structures have shown a lower erosion rate than the amorphous domains. The retarded
water penetration to the polymer structure in the crystalline domain, cause this slower
rate of erosion30. Shakeshef et al.31 prepared the poly (sebacic anhydride) (PSA) using
melt polycondensation. They showed faster erosion rates for polyanhydrides with
amorphous domains in comparison to more crystalline structures of the polymer with
slower erosion rates. Adding drugs or model compounds to polyanhydrides may lower
the cross-link density, leading to different erosion rates. For example, loading 2% bovine
serum albumin to the poly (fumaric-co-sebacic anhydride) (p(FA-SA)) 20:80
polyanhydride has shown increased degradation rate of the system32. Several studies have
shown various erosion rates using different mole ratios of monomers. The copolymer of
the SA and 1,3-bis( p-carboxyphenoxy)propane or p(CPP-SA) was used to develop the
Gliadel wafer33. The slower erosion velocity of the p(CPP-SA) when it has more CPP in
its structure28 is a good example of the effect of polymer composition on its erosion
behavior. In another study, series of poly[bis( p-carboxyphenoxy)alkanes] made of six
methylene units showed a very slower erosion rate in comparison to the polymer made of
one methylene unit (three-fold decrease was observed in the release rate)30.
Polyanhydrides erosion is also dependent on the pH and the temperature of the
environment, the geometry of the polymeric DDS, and the flow rate of the media in
contact with the polymer, besides the mentioned parameters.
The pH of the solution might change the erosion of polyanhydrides. The in vitro
degradation of the copolymer derived from SA and FA were conducted in Phosphate
Buffered Saline (PBS) with different pHs by Santos et al.34. Three different polymers
(p(FA-SA) 70:30, p(FA-SA) 50:50, and p(FA-SA) 20:80) were degraded at three pHs
equal to 8.8, 7.4, and 4.2. Results showed significantly higher erosion rates of all three
polymers at pH=8.8 than the neutral and acidic conditions. Besides, the degradation of
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p(CPP) matrices at pH ranging from 7.4 to 10 showed more stability of polyanhydrides at
lower pHs30.
As polyanhydrides predominantly undergo surface erosion, the geometry of delivery
systems made of polyanhydrides is of high importance. The erosion of polyanhydrides as
microparticles are faster than the rate of erosion from macro-scale delivery systems made
of polyanhydrides27. Another study showed the dependency of the amount of the water
uptake for p(CPP-SA) 40:60 to the geometry and the size of the polyanhydride delivery
system which can change the erosion kinetics of the polymer35.
To better simulating the in vivo situation, shaking the PBS solution could be applied
during in vitro experiments. This agitation is the representative of the mass transfer
affecting the erosion of the polymer. Sheh et al.36 studied the effect of the mass transfer
on Poly (fatty acid dimer: sebacic acid) (p(FAD:SA)) 50:50 by conducting the
degradation test at three shaking rates (0, 60, and 120 rpm). No obvious differences were
observed in this study for the erosion of this polymer with three different agitation
speeds. Gopferich et al. and the Langer group have extensively studied the degradation
and erosion of conventional polyanhydrides and parameters affecting their erosion
behavior 27,37,38.

2.2.3

Parameters affecting the Erosion of Photopolymerized Thiolene Polyanhydrides

Full characterization of a new polyanhydride and investigation of the impact of essential
parameters on its erosion is necessary for the newly introduced polymer in order to be
utilized as a CRS. In 2009, a new type of linear and cross-linked polyanhydrides was
synthesized using thiol-ene chemistry. The advantages of synthesizing these
photocrosslinkable elastomeric polyanhydrides over conventional polyanhydrides are
discussed in section 2.2.1. Recently, few studies have been conducted to explore the
erosion mechanism of this type of polyanhydrides. For the first time, Shipp et al.25
synthesized linear and cross-linked polymers using 4-pentenoic anhydride (PNA), 3,6dioxa-1,8-dithiooctane (EGDT), and tetrakis(3-mercaptopropionate) (PETMP) monomers
in the presence of a photo-initiator. They showed the surface erosion of this type of
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polymer experimentally by measuring the mass loss of polymers in PBS at pH=7.4. Four
different polymer compositions were synthesized to show different erosion times ranging
from 30 to 70 hours. In another study, Rutherglen et al.39 characterized the same
polymers thermo-mechanically for better understanding of the polymers’ properties.
The erosion and toxicity study for a specific cross-linked thiol-ene polyanhydride made
of PNA and PETMP were conducted by Poetz et al.40. In this study, they determined the
mass loss profile of this polymer, showing an almost 10 hours induction period and total
erosion time of 25 hours for a polymer with slab geometry (2 × 10 × 10 mm). The
erosion front (the thickness of water penetration during the induction period) for this
polymer was measured to be almost 400 μm. The variation of the pH in the media caused
by the degradation products during the polymer erosion was monitored to calculate the
hydrolysis rate as a function of the pH. They also added 1wt% of a hydrophilic dye to
the polymer and showed that the dye release profile qualitatively followed the mass loss
profile of the polymer.
In 2015, the same group41 synthesized a new semi-crystalline thiol-ene polyanhydrides
with a broader range of erosion time starting from 24 hours to almost 10 days for
polymers with cylindrical shape (10 mm diameter, 5 mm height). They showed the
surface erosion of these polymers made of PNA, PETMP, and 1,6-hexanedithiol (HDT)
with different initial mole ratios of monomers. In this study, the effect of the crystallinity
of polymers on erosion time was investigated. Polymers with almost 60 % crystallinity
showed ten times slower erosion rates than the polymer with the amorphous domain.
Effect of adding various amounts of lidocaine (1, 2, and 3wt %) to polymers on the
erosion of polymers showed slightly faster erosion for polymers loaded with drugs.
There are essential parameters that substantially affect the erosion of thiol-ene
polyanhydrides that have not been explored yet. In this thesis, a comprehensive study on
erosion (mass loss) of different thiol-ene photopolymerized polyanhydrides was
conducted and the effect of various factors on polymers’ mass loss and erosion rates is
presented. The major part of chapter 3 of this thesis discusses the impact of parameters
such as the temperature and pHs of media, the geometry of polymers, loading drugs or
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model compounds to polymers, and media flow rate on erosion of cross-linked thiole-ene
polyanhydrides.

2.3

Diseases and Release Profiles

Controlling the temporal profile of drug release is vital for achieving the optimal
therapeutic effect. Despite significant advances in controlled release technologies, most
of DDSs only offer monotonic, or constant (i.e., sustained) release profiles. However,
different types of clinical circumstances require different types of timed-release. These
temporal patterns are mostly defined by the effect of circadian rhythm on different
clinical circumstances, giving rise to specific rhythms of medical conditions during the
24 hours of the day. Besides, various factors, such as the patients’ condition, age, and
gender necessitate patient-specific treatments via personalized medicine.

2.3.1

Circadian Time Structure

The study of the biological rhythm is called chronobiology, and the consequence of
several

biological

rhythms

is

the temporal

organization of human bodies.

Suprachiasmatic nuclei (SCN) which are located in the hypothalamus control the human
circadian rhythm42. Figure 2-7 illustrates the human circadian time structure. In this
figure, sleep time is considered from 10:30 p.m. to 6:30 a.m. (the dark side) and the rest
of the time during the 24 hours of the day is considered as activity time for a person with
normal activity. The graph displays the peak of the basal gastric acid secretion and white
blood cell count (WBC) at late night while the concentration of the hemoglobin and
insulin is at the highest level at noon.
This circadian rhythm governs the cells- to organs-level activities of our body, and hence
affect the occurrence and even severity of medical conditions. For example, peptic ulcer
attack and gall bladder occur mostly at night while the myocardial infarction (MI) or
heart attack occurs most frequently in the morning. These patterns of the symptom’s
severity show the necessity of precise treatments in which the exact amount of
therapeutics are released in the body during exact times of the day, for specific durations.
For example, Gonadotropin-releasing hormone (GnRH) necessitates pulsatile release for
therapeutic effectiveness. Decreasing release profiles are beneficial for diseases that are
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worse in the morning, including rheumatoid arthritis, asthma, and angina pectoris.
Patients with osteoarthritis suffer from stronger pain in the afternoon and should benefit
from an increasing release profile. Moreover, some agents or drugs require a particular
administration profile during a specific period of time. For instance, patients who suffer
from attention deficit hyperactivity disorder (ADHD) require a bimodal release profile of
Ritalin-LA43. In addition to the temporal profile, for some drugs (e.g. anticoagulants,
antihypertensives, and antiepileptics), achieving an accurate plasma concentration
throughout the medication is very important due to the narrow therapeutic range and
severe side effects.

Figure 2-7: Human circadian time chart. Peaks of some biological features during 24 hours of
the day in a person with normal daytime activity. The chart shows the Thyroid-stimulating
hormone (TSH) as well as the growth hormone and melatonin peak in the bedtime while the
concentration of the adrenocortical hormone (ACTH), follicle-stimulating hormone (FSH), and
luteinizing hormone (LH) is at the highest level at the start of the daytime. Reproduced from Ref
43

with permission.

“Personalized medicine” in drug delivery systems has emerged as an approach to enhance
the efficacy of treatments by designing customized therapy that follows the individual
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patient’s needs. For example, a release profile that mimics the circadian rhythm of the
patient is considered advantageous for insulin dosing and enables innovative methods in
cancer treatment, highlighting the importance of developing CRSs that can adjust and
customize the release profile for different circumstances.

2.4
Recent Developments in Fabrication Methods of
DDSs to Achieve Adjustable Release Profiles
Several fabrication methods exist for manufacturing different DDSs. Although traditional
compression tableting is still being used by pharmaceutical industries for manufacturing
tablets and capsules44, increased awareness of individualized therapy and introduction of
various biodegradable polymers with adjustable physicochemical properties, encourage
the development of fabrication methods for manufacturing advanced controlled DDSs. In
this section, recent developments in fabrication methods of advanced DDSs that enable
releasing of drugs at controllable rates is reviewed. The focus of this section is on the
micro-fabrication technique and the 3D printing technology that has attracted attention in
recent years for the manufacturing of advanced controlled DDSs.

2.4.1

Micro-fabrication Technology

Micro-fabrication was originally adopted from the microelectronics industry and has been
used for manufacturing advanced DDSs. Recently, micro-fabrication technology has been
employed to manufacture high-throughput assays for drug discovery and tissue
engineering applications45. Moreover, some issues of oral drug delivery can be addressed
when micro-fabrication is used, owing to its ability to manufacture tiny features while
providing control over the shape or geometry of delivery devices.

2.4.1.1

Micro-fabrication Methods: Photolithography Process

Micro-fabrication for creating delivery devices generally consist of repeated steps,
including film deposition and photolithography. First, the desired two-dimensional (2D)
features which are designed by a computer-aided design (CAD) software beforehand are
printed as a photo-mask. Photolithography steps will in turn transfer the pattern to a
substrate. In the first step, a photo-sensitive polymer coats the substrate to the desired
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thickness. Then, the coated substrate is exposed to the Ultra Violet (UV) light while the
photo-mask is located above the substrate and below the mask aligner (UV-light source).
Finally, the cross-linked photo-resist encompasses embossed features, while the
remaining uncross-linked polymer is washed away. Using the standard photolithography,
it is possible to achieve features with fine resolution of 0.5 to 1 μm 46.
Based on the ultimate application of these micron-sized features, a hard substrate such as
silicon can be used as a master mold for making the inverse replica of soft elastomers.
This process is called soft-lithography (Figure 2-8 A-F) in which usually poly
(dimethylsiloxane) (PDMS) is used as the soft elastomer material
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. A combination of

the micro-fabrication techniques such as standard photolithography with repeated replica
molding steps allows for easy, rapid, and precise manufacturing of drug delivery devices
at relatively low costs47,48. Fine features on a PDMS mold can be used to make channels
through which minute amounts of fluid flow, creating a platform called microfluidics.
Microfluidic devices have been extensively used for tissue engineering applications
particularly for lab-on-a-chip studies, or as high-throughput platforms for drug screening.
Microfluidics also has been used for fabrication of controlled release micro-particles as
well as polymeric micro-containers in drug delivery devices 49.
Several characteristics of micro-fabrication technology can help simplify achieving
CRSs. Various devices have been micro-fabricated that are capable of delivering drugs
locally, on-demand, or through programmable devices. Several papers reviewed various
micro-fabricated controlled DDSs developed over the past 20 years50,51 covering both
programed polymeric systems, on-demand or remotely programmable devices.
Programmed polymeric systems are designed to deliver therapeutic contents in micro or
nanoparticles at a pre-determined rate. The release of drugs from on-demand delivery
devices is usually controlled remotely by operators. We review the advancement in the
development of micro-fabricated programmable and on-demand devices designed for
controlling the drug release profile.
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Figure 2-8: Schematic illustrations of the standard soft lithography process. A, B) The
deposition of the photo-resist on a silicon wafer. C, D) the exposure of the coated substrate
to the UV-light through the printed photo-mask. E) Pouring the PDMS on the embossed
features of photoresist and peeling off the cured PDMS. F) Final PDMS molds containing
designed features. Reproduced from Ref 46 with permission.

2.4.1.2

Microchip DDS

In oral dosage forms, many therapeutic molecules suffer from poor bioavailability and
require other methods of delivery. Local DDSs that ensure the delivery of therapeutics to
the proper site can enhance the effectiveness of treatment and potentially eliminate the
harmful side effects to the liver that are often caused by oral means of delivery52.
Implantable DDSs have attracted increasing attention for improving the local delivery
and patient compliance.
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Microchips as CRSs were originally introduced by Robert Langer and coworkers53 and
were designed to generate a long-term pulsatile release. Achieving pulsatile release is
particularly important because the human body secretes molecules such as insulin3,
growth hormone, and GnRH in a pulsatile manner. Accordingly, therapies targeting
disorders related to these molecules need to be released in a pulsatile fashion to achieve
an optimal therapeutic effect. In 1998, Robert Langer and his group conducted a proofof-concept study with a solid-state silicon microchip that could provide on-demand
controlled release of substances. In this microchip, single or multiple chemical substances
were entrapped in ~25nl reservoirs covered with thin gold membranes acting as anodes
(Figure 2-9A). The release mechanism was based on the electrochemical dissolution of
individual anode membranes upon application of voltage. The fabrication of the
microchip was a sequential process of photolithography and microelectronic processing
techniques. The proof-of-concept study indicated the ability of this model microchip to
generate pulsatile release profiles of chemical substances53.
In 2003, the Langer group proposed a similar platform for achieving pulsatile release in a
programmed manner without requiring external stimuli to initiate the release. Similar to
the previous platform developed earlier, the device encapsulates single or multiple types
of chemicals in 36 micro-sized reservoirs, covered with polymeric membranes on the one
side (Figure 2-9B). The characteristics of this polymeric membrane that regulates its
degradation rate (e.g., molecular weight, and compositions) determine the time of the
release from the reservoir covered with this membrane. The reservoir-covering
membranes are made of PLGA with various molecular weights, adjusting their rate of
degradation and hence the time at which the chemicals (human growth hormone, dextran,
and heparin) are released from each reservoir. The biodegradable polymeric device
showed the ability to release four pulses of multiple chemicals over several months, and
they successfully obtained a pulsatile release of bioactive heparin over 142 days (Figure
2-9C, D)54.
The increasing interest in implantable DDSs was followed by the work of Santini and
coworkers on developing advanced on-demand and programmed microchip platforms55.
In 2006, they further enhanced the membrane-covered reservoir design to achieve
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remotely controlled pulsatile release of Leuprorelin protein over 6 months in dogs56. The
release of the therapeutic protein from 100 individual reservoirs was regulated
electrothermally, and controlled by telemetry. This method of membrane removal
(electrothermal) is preferable over electrochemistry, because it is independent of the
chemical compounds of the surrounding environment, as well as being considerably
faster. The results for the in vivo experiment of the remotely-controlled microchips
indicate the feasibility of the delivery of therapeutic polypeptides using implantable
DDSs56.
The first clinical trial of implantable microchip devices for drug delivery was carried out
in 2012. The therapeutic compound delivered in this trial was an osteoporosis treatment
(Human parathyroid hormone fragment, hPTH) that generally requires repeated injections
of daily dosage and hence has low patient compliance. The microchip device used in this
clinical trial has dimensions of 13.0 mm × 5.4 mm × 0.5 mm with 20, 600-nL wirelessly
controlled reservoirs containing lyophilized hPTH. The microchips were implanted in 8
women who were suffering from postmenopausal osteoporosis, in the subcutaneous space
of the abdomen. The devices were implanted (Figure 2-9E) for four months and were
controlled to deliver the once-daily dosage of the drug. The release of the reservoirs is
controlled by a computer program that sends and receives information wirelessly to and
from the implant, driving the precise timing of dose delivery. Microchip dosing proved
capable of providing pharmacokinetic profiles similar to multiple subcutaneous
injections, without the burden and pain of injections. This clinical trial demonstrated the
potentials of this platform to improve current chronic delivery methods, e.g. repeated
insulin injections for diabetic patients57,58.
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Figure 2-9: Microchip controlled DDSs. A) The implantable silicon microchip device for
controlling the release profile of the drug using the electrochemical dissolution of anodes, (i) a
view cut showing the reservoirs (ii) enlarged view of a single conical reservoir. Reproduced from
Ref 53 with permission. B) The schematic of the microchip device, including the reservoircontaining substrate which is fabricated by a degradable polymer. C) Cumulative percentage of
the initial loading of the C-dextran. Each symbol indicates the data from different devices in
which the membranes are made of copolymers with different molecular weights. Increasing the
molecular weight of the polymeric membranes caused the release times of the chemicals to
increase. Arrows show the opening time for each membrane. D) Cumulative percentage of the
initial loading of the H-heparin. Increasing the molecular weight of the polymeric membranes
results in increased release times of the chemical. Reproduced from Ref 54 with permission. E)
The final implantable microchip device and its location in the patients’ body to release the hPTH
(1-34). Reproduced from Ref 57,58 with permission.
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Implantable microchips are attractive means of drug delivery and have proved
advantageous in different applications. However, these devices come with their
limitations. Implantable means of delivery are inherently invasive, requiring implant
surgery to place the DDSs and an explant surgery to remove the device from the body
after the dosage is completed. Patients may need to take painkillers and/or antiinflammatory medications to alleviate the discomfort after surgeries. Current implantable
DDSs have not incorporated measurements of the drug’s concentration after or during the
release; however, a closed-loop control on the release from the device is necessary to
avoid under- or over-dosing of the drug. In addition, the methods used for the opening of
the reservoirs in proposed microchip devices are not reversible, and accordingly, quality
assurance on whether the membrane will be appropriately removed as programmed or
upon external stimulation, before implantation, has not been reported. In the clinical trial,
patients tolerated the size of the implant, with the microchip device enclosing only 20
reservoirs. An increased number of reservoirs is necessary for treatments requiring more
frequent dosing and longer delivery periods, which may be associated with larger implant
sizes. Despite attractive features implantable DDSs offer, their widespread development
and use are constrained to these limitations, leaving oral dosage forms yet the most
commonly used form of delivery57,1.

2.4.2

3D Printing Technology for Manufacturing Oral Dosage
Forms

The oral routes of the drug administration are preferred by patients since they are
affordable, noninvasive, and convenient for the patients. Accordingly, oral controlled
DDSs have been the focus of many research work in personalized medicine1. 3D printing
technology has emerged as an attractive fabrication method in the food and
pharmaceutical industry due to its ability to manufacture objects with fine features.
Modified-release and/or personalized oral dosage forms have been fabricated using 3D
printing technology. The oral dosage forms are either directly 3D printed, or indirectly
fabricated where molds or containers are 3D printed. Among various types of 3D printing
technologies,

powder-bed

inkjet,

fused

deposition

modeling

(FDM),

and

stereolithography (SLA) have been the most commonly used methods for fabricating
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solid oral dosage forms59. In what follows, a review on the application of these three 3D
printing technologies in the fabrication of solid oral dosage forms for achieving
adjustable release rates is presented.

2.4.2.1

Powder-bed Inkjet 3D Printing

The first 3D printer to receive FDA approval for pharmaceutical applications was
Aprecia and was based on inkjet printing a binder solution on a power bed. It was used
for printing tablets for epilepsy. The inkjet powder-bed 3D printing process (Figure
2-10A) consists of spreading a powder layer onto a plate (bed) with a roller, and
introduction of the binder solution to specific areas onto the powder to bind its particles
in that area, based on the CAD design. This forms one layer of the structure of interest.
The process is additive, meaning the same steps are repeated for each additional powder
layer until the desired geometry is built. At last, the residual powder is brushed away. The
structures fabricated by this 3D printing technology have high porosity which is
beneficial for the production of immediate release tablets60.
Cima and coworkers were one of the first groups that fabricated solid dosage forms using
powder-bed 3D inkjet printing. They used standard pharmaceutical materials and varied
the polymer contents to obtain delayed-release tablets. They fabricated tablets that
underwent two different release mechanisms, namely erosion and diffusion. In erosionbased tablets, by adjusting the quantity of the polymer, they achieved lag times (the time
before the drug starts releasing) varying from 25 to 50mins (Figure 2-10B). Increased
polymer content resulted in longer lag times and hence slower release. In tablets with a
diffusion-based release, an increase in polymer content resulted in a reduction in the
maximum rate of release. The lag time was not affected by polymer content in diffusionbased tablets. The release profile characteristics were proved adjustable through
modifying the quantity of polymer in inkjet 3D printers60.
In a different study, they used the same powder-bed inkjet 3D printing system to develop
four different solid dosage forms with distinct release behaviors61. The first tablet was
designed for immediate/extended release pattern (Figure 2-10C-i). These tablets consisted
of two sections, both loaded with chlorpheniramine maleate as the drug. The two sections
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had different polymeric contents and hence had specific pH-sensitive release
mechanisms. Experiments showed that the release of the drug from the first section
happened with a 10min lag time, whereas the second section released the compound over
an extended period of 7hrs (Figure 2-10D). The second dosage forms were breakaway
tablets (Figure 2-10C-ii). These tablets were programmed to split into two drug-loaded
sections by the fast erosion of a part separating the two. The drug-loaded sections erode
in gastric fluid over a 30-45 min period. The third type of tablet was designed to achieve
enteric dual-pulse release (Figure 2-10C-iii). A total amount of 3.4 mg diclofenac sodium
was printed as two separate compartments into the tablet. As for the fabrication, they
printed 6 layers of powder with only the binder, followed by a drug-containing layer. The
same procedure was repeated, followed by two final layers of powder without drug. The
release mechanism is erosion and hence the two diclofenac compartments are released in
turn, making two pulses at 1 and 8 hours, as indicated by the release experiments results.
The dual pulse devices were designed such that a portion of the drug be released in
response to the low pH in the stomach whereas the rest would be released at high pH
conditions in the intestine. The tablet design is showed in Figure 2-10C-iv61.
In 2009, Yu et al.
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reported powder-bed inkjet 3D printing of a doughnut-shaped DDS

with zero-order release kinetics. The tablet design consisted of a model drug in the
middle, and release-retardant material containing ethyl cellulose (EC) as the barrier
covering the top, bottom, and outer surface of the tablet. The results of the release
experiments indicated linear profiles, irrespective of the diameter of the central aperture,
the outer diameter, or the table height. The release rate was adjustable by modifying the
thickness, and quantity of EC of the outer surface covering the core. This study
demonstrated the application of powder-bed 3D inkjet printing for achieving zero-order
release kinetics throughout the entire dissolution process.
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Figure 2-10: Directly printing the solid oral dosage forms using the powder-bed inkjet 3D
printing process. A) The schematic illustration of the powder-bed inkjet 3D printing process. B)
Variation of the lag times in releasing the chemicals by adjusting the content of the polymer.
Reproduced from Ref

60

with permission. C) Four different tablets printed by the powder-bed

inkjet 3D printer machine: schematics showing (i) immediate-extended release pattern tablet, (ii)
the breakaway tablet, (iii) the enteric dual-pulse release tablet, and (iv) the dual-pulse release
tablet. D) The release profile for the immediate-extended tablet. The first section made of E100
20% w/w started releasing after 10 minutes (lag time). The second section made of Eudragit
RLPO and acetone released its content over an extended period of 7 hours. Reproduced from Ref
61

with permission.
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In 2012, Genina et al. reported a novel method for fabricating solid dosage forms. It
combines inkjet printing with flexographic printing to achieve controlled release patterns
of therapeutics. They studied the impact of using three different paper substrates as
porous carriers for DDSs on release characteristics. Release kinetic studies were
conducted on tablets before and after coating various thickness of EC polymer film using
flexographic printing. The release profile can be adjusted to decreasing or constant by
changing the number of coating layers and/or the thickness of the coatings63.
In 2017, Kyobula et al. reported a solvent-free 3D inkjet printing of solid dosage forms64.
They fabricated matrix tablets containing a biocompatible and FDA approved wax as the
carrier and a practically insoluble drug. In this study, they fabricated tablets with
honeycomb geometries. They evaluated the ability to control the drug release profile by
modifying the honeycomb characteristic, e.g. cell diameter and hence, the surface area.
Larger than middle-sized honeycomb structures resulted in lower release rates due to a
decrease in tablet surface area. This design allowed control over drug release rates by
modifying the geometry65.

2.4.2.2

Fused-deposition Modeling (FDM)

Another type of 3D printing is fused-deposition modeling (FDM). In FDM methods,
thermoplastic polymer filaments are extruded. Once filaments are in a melted semi-liquid
form, they pass through a nozzle with elevated temperature. Filaments exit the heated
nozzle and are deposited on the build plate on specified locations where they will be
hardened. FDM 3D printing poses some advantages that made this technology suitable
for manufacturing oral dosage forms. It can produce tablets with higher resolution
compared to inkjet 3D printing, allowing for more accurate drug release. FDM-based
machines are also capable of printing relatively intricate designs to achieve modified
release profiles. More importantly, FDM 3D printing is easily set up and is relatively
cheap59. Studies in which FDM-based 3D printers have been used to fabricate oral tablets
can be divided into two classes: direct printing of tablets and printing containers/molds,
helping the preparation of controlled-release tablets indirectly. A brief review of some
studies in both categories is presented below.
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Goyanes et al. fabricated tablets using the combination of FDM and hot-melt extrusion
(HME) processing. They showed the potential of FDM technique in manufacturing oral
dosage forms by producing tablets with different geometries, which is not easily
achievable using conventional methods of tablet fabrication, e.g. powder compaction.
They successfully printed tablets with five different geometries (Figure 2-11A). The
filament was made of a water-soluble polymer (polyvinyl alcohol, PVA) loaded with
paracetamol. They investigated the impact of tablet geometries, including the tablet
surface area, volume, and the surface area to volume ratio (SA/V ratio) on drug release
profiles by conducting separate experiments. Results showed that the fractional drug
release rates were dependent on the SA/V ratio of the dosage forms. When the SA/V
ratios for all the tablets were identical, almost all of them released 90 percent of their
loaded drugs in 10 hours regardless of the differences in surface areas and the volumes of
the tablets (Figure 2-11B). This study indicated the potential of FDM 3D printing as a
low-cost fabrication process for manufacturing tablets with relatively complex
geometries, which allows for controlling the release rate of the drug by adjusting the
geometry of dosage forms66.
In another study, Tagami et al. fabricated composite tablets using the FDM 3D printing
method to tune the release rate of a model drug (calcein) loaded in PVA.

Filler

components were either the water-soluble polymer (PVA) or a water-insoluble polymer
(PLA) which did not contain any drug67. They used a dual nozzle 3D printer to print the
drug component and the filler component separately. They produced different tablets with
both PVA and PLA fillers (Figure 2-11C). By changing the thickness of the PLA, they
could adjust the lag time. Results of in-vitro drug release tests indicated that an increased
surface area increases the initial release rate of the model drug from the tablets. They
designed two different shapes of the drug component with increasing and decreasing
surface areas. Results indicated zero-order increasing and decreasing release rates,
respectively. They also produced a cylindrical drug component with constant surface area
and increased the thickness of the covering PVA to increase the lag time (Figure 2-11D).
In addition, they showed the potential of the composite tablets to deliver drugs to certain
locations through the GI tract by adjusting the release timing. Therefore, these tablets
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with various wall thicknesses can be used as alternatives to pH-sensitive or other
exogenously stimulated DDSs67.

Figure 2-11: Direct FDM printing of oral tablets. A) Five different tablet geometries printed by
FDM technique. B) Tablets released their contents in 2-3 hours when the SA/V ratio for all of
them was the same. Reproduced from Ref 66 with permission. C) Eight calcein-loaded PVA/PVA
composite tablets (top) and four calcein-loaded PVA/PLA composite tablets (bottom). D) By
increasing the thickness of the covering layer, the lag time increased. Reproduced from Ref

67

with permission.

Despite the attractive properties of FDM for directly printing tablets and its potential for
manufacturing the personalized treatments, it comes with certain limitations. FDM
operation involves exposure of the polymer to high temperatures, which is only tolerated
by thermoplastic polymers with a high glass transition temperature. These polymers have
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relatively high molecular weights, and therefore the resultant structure exhibits extendedrelease patterns that are not always suitable for patient dosage needs68.
FDM can be used indirectly for manufacturing controlled-release tablets. In 2015, Andrea
Gazzaniga and his group used FDM technology to explore the possibility of using 3D
printing for fabricating Hydroxypropyl cellulose (HPC)-based capsular controlled DDSs.
The capsular DDSs design consisted of a cap and a body. They obtained the release
characteristics and evaluated the possibility of obtaining a pulsatile release with this
design. Lag time (in this study is defined to be the time passed before 10% of the
chemical is released), and pulse time (the time duration between release of 10% and 90%
of the drug), were measured 70min and 10min, respectively. The results indicated the
potential of FDM for rapid prototyping of capsular DDSs, and hence avoiding the timeconsuming process of mold development and enhancement69.
Andrea Gazzaniga and his group improved the above design in an attempt to provide
more flexibility with the capsular devices70. They modified the capsule design and
composition to encapsulate different therapeutic compounds. The capsule was partitioned
into two hollow halves, with the timing of release from each half independently during
the capsule design by changing the thickness and/or composition of the compartment.
Using combinations of compartment wall thickness and polymer characteristics, they
could achieve immediate, enteric, and pulsatile releases. They obtained the release profile
of the capsules, with compartments fabricated from PVA filaments with different
thicknesses (Figure 2-12A). Release profiles of capsules with the same compartment
thickness and different compartment compositions were also obtained (Figure 2-12B).
This design can be particularly advantageous for improving patient compliance by
ensuring the dosing schedule of prescribed with therapies that are not compatible or
interact in gastrointestinal tract71.
In another study, Sun et al.72 fabricated tablets using a commercially available FDM
printer to achieve pre-determined release rates of drugs. They fabricated polymeric
tablets within molds and containers created by extruded polymeric filaments. The
impermeable container made of PLA was utilized to seal all surfaces of the drug-
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containing polymer. Drugs were released from the one side that was not covered by the
container. Different release patterns were obtained from tablets due to the near zero-order
erosion of polyanhydrides from the surface exposed to PBS. This design was also capable
of incorporating two model drugs into one tablet and releasing them with different
patterns. (Figure 2-12C, D). This study shows the potential of FDM 3D printing
technology for creating containers and molds for achieving different tablet designs.

Figure 2-12: FDM printing of containers and molds to create controlled-release tablets. A) The
capsular DDS with different thicknesses, producing a two-pulse release profile. B) Two pulse
release profile of the capsular DDS achieved by having two different materials for each
compartment, with consistent thicknesses. Reproduced from Ref70 with permission. C)
Customizable release rates of drugs (e.g., decreasing and pulsatile) from erodible tablets
fabricated by containers and molds printed by FDM 3D printers. D) Tablets for releasing two
drugs with different release rates at the same time. Reproduced from Ref 72 with permission.

FDM is an interesting substitute for conventional fabrication methods of tablets due to its
potential in manufacturing desired geometries to achieve a more accurate dosage. Unlike
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conventional additive manufacturing methods, FDM can be used to create rounded
corners which enhances patient compliance. However, there are limitations to this
method which reduces its flexibility and wide-spread use. The high temperature required
during FDM steps can damage thermally labile drugs. Besides, only a few biodegradable
thermoplastic polymers can tolerate such high-temperature conditions. Although FDM
has been used in fabrication of various geometries, the resolution of these printers may
not be high enough to achieve the desired surface quality, as well as acute angles required
in some dosage forms.

2.4.2.3

Lithography-based 3D Printing

Research on Stereolithography (SLA) 3D printing has been around since 1970s; however,
Chuck Hull introduced the term in 1984 and was granted the patent for SLA in 1986.
SLA technology is based on photopolymerization, that is, polymerization and hence
solidification of the liquid resin upon exposure to laser. Photopolymerization is
conducted in an additive manner (similar to other 3D printing technologies) where for
each layer a CAD design guides the depth of the laser focus, obtaining localized
photopolymerization, and eventually producing the 3D object of interest. SLA offers
several advantages over other 3D printing technologies previously reviewed. In contrast
to FDM methods, SLA does not expose the materials to high temperatures, and therefore
it is suitable for fabricating DDSs with thermally labile therapeutics. SLA’s resolution is
superior to other 3D printing technologies and is only restrained by the laser width73.
Digital light processing (DLP) 3D printing is also a lithography-based method with
higher resolution and printing speed in comparison to SLA 3D printing. Typically, a UVcurable resin that can be printed by SLA would also be used in DLP. SLA utilizes lasers
to cure the photo-curable solution point by point, while DLP uses a digital projector to
cast and cure an entire slice of objects. Fast manufacturing times for the fabrication of
complex structures with high resolution can be achieved by both methods, especially by
DLP 3D printers. Recently, there has been increased attention to use DLP for
manufacturing oral dosage forms74.
The use of SLA technology for printing oral dosage forms was introduced by Simon
Gaisford and Abdul W. Basit, and coworkers73. In this study, Polyethylene glycol
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diacrylate (PEGDA) and polyethylene glycol 300 (PEG 300) were used as monomers in
different ratios, aiming at obtaining different release kinetics at each ratio. The SLA 3D
printed tablets with two different drugs (paracetamol and 4-ASA) are shown in Figure
2-13A. Tablets were printed in torus shapes, which are complicated structures to achieve
by other manufacturing methods. An increase in the PEGDA portion resulted in slower
release rates. The release kinetics proved independent from changes in the pH, as shown
in the release profile graphs (Figure 2-13B, C)73. This study proved the potential of SLA
3D printing in the fabrication of high-resolution solid oral dosage forms from thermally
labile drugs, with adjustable release rates to achieve immediate or extended profile.

Figure 2-13: SLA printed tablet structure and release behavior. A) SLA printed tablets with
paracetamol (top row) and 4-ASA (bottom row) as model drugs. Each row from left to right show
tablets with PEGDA to PEG 300 ratios of 3.5:6.5, 6.5:3.5, and 9:1. B) The release profiles of the
paracetamol from tablets with different polymer ratios. The release is slower for higher PEGDA
percentages and is insensitive to changes in the pH. C) The release profiles of the 4-ASA. Slower
release from higher PEGDS tablets was observed. The release showed independent from pH.
Reproduced from Ref 73 with permission.

SLA 3D printing technology has offered benefits over conventional 3D printing methods
that are promising for further advances in fabricating personalized oral dosage forms. The
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main limitation associated with SLA 3D printing, however, is the limited number of
photocrosslinkable resins that are at the same time non-toxic, safe, and biocompatible.
In this section, recent developments in the fabrication of advanced controlled DDSs for
achieving various release profiles of drugs are reviewed. Micro-fabrication has been used
to create microchip devices that are implanted in the body to release drugs with predetermined rates of release. Despite the high resolution of micro-fabrication methods and
their ability to produce high-throughput platforms, several limitations of using
implantable microchips (discussed in section 2.4.1.2), make the oral controlled DDSs the
most desired option. Numerous studies such as studies reviewed in section 2.4.2 show
substantial progress in the fabrication of polymeric oral tablets with adjustable release
profiles using 3D printing technology. Most of the studies reported monotonic or constant
release profiles of drugs, while some others achieved more complicated release profiles
such as pulsatile release rates. The more complicated release patterns were achieved by
more elaborate tablet designs and specific fabrication techniques, demonstrating the
feasibility of creating tablets with various release patterns of drugs. Although these
studies show that personalized medicine is no longer a dream, there exist some
limitations in fabrication of modified release tablets that can hinder their widespread
application. Some of these limitations can be addressed by improving the tablet designs
and using appropriate fabrication methods. For example, the resolution of the fabrication
method can determine the precision of the release rates. Micro-fabrication techniques
such as photolithography are capable of creating miniaturized fine features with high
resolution, whereas the resolution of the inexpensive and commercially available 3D
printers such as FDM-based printers are not sufficient for printing tablets with complex
geometries. SLA or DLP 3D printers have higher resolution for producing tablets;
however, the limited number of printable materials that are compatible with these types
of machines reduces their widespread application in producing controlled-release tablets.
In addition, scalability and high-throughput manufacturing is a critical characteristic of
any potentially successful fabrication method. High-throughput manufacturing is
currently a significant challenge in production of advanced controlled DDSs with
adjustable release rates. Most of the studies described in section 2.4.2, reported
fabrication of a single tablet in each experiment, reducing the chances of their practical
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use in clinical settings. Manufacturing each tablet can take considerable amount of time,
and the reproducibility level is low.

2.5

Objectives

The objectives of this study are to:
(i) prepare and characterize surface eroding polymers used in the fabrication of drugloaded tablets, and to study the mass loss profile of the polymers comprehensively.
(ii) develop a high-throughput fabrication platform for manufacturing the tablets that can
provide adjustable drug release patterns.
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Chapter 3
A Comprehensive Study on Mass Loss Profile of Thiolene Polyanhydrides

3

In this chapter, we explore the effect of different parameters on mass loss (erosion)
profiles of polyanhydrides synthesized by thiol-ene photopolymerization. A comparative
study on release kinetic models fitting for better understanding of the polymers’ erosion
behavior is also described.

3.1
3.1.1

Materials and Methods
Materials

4-pentenoic anhydride (PNA), 2, 2-(Ethylenedioxy)diethanethiol (3,6-Dioxa-1,8-octanedithiol,

EGDT),

Pentaerythritol

tetrakis(3-mercaptopropionate)

(PETMP),

1-

Hydroxycyclohexyl phenyl ketone, and acid orange 10 (orange G) were purchased from
Sigma Aldrich Chemical Co. and were used as received. 3D printer acrylate-based resin
(Clear 2005T) was purchased from MiiCraft. Sylgard 184 Silicone Elastomer prepolymer and curing agent were purchased from Ellsworth Adhesive Chemical Co., for
making PDMS.

3.1.2

Polymer Synthesis Procedure

1-Hydroxycyclohexyl phenyl ketone (photo-initiator, 0.1wt %) was weighed and placed
into a 15 ml Falcon tube. Then, PNA was transferred into the tube, followed by the
mixture of EGDT and PETMP.

The solution was mixed to obtain a homogenous

mixture. The initial mole ratio of PNA to the total amount of monomers containing thiol
groups (EGDT and PETMP) was 100:100. In this study, four different initial mole ratios
of PNA to PETMP and EGDT were prepared and used including PNA: PETMP: EGDT =
100:100:0, 100:75:25, 100:50:50, and 100:25:75. The homogenous mixture was then
purged under the inert gas (nitrogen or argon) for 3 minutes and was transferred to PDMS
molds. The pre-polymer solution in molds was exposed to UV-light (CL-1000 UVP
Cross-linker) equipped with 365 nm UV lamps (intensity=~5 mW/cm2) for 5 minutes.
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For some of the experiments, we added a model compound for which acid orange 10 (13wt %) was weighted and added to the purged solution and mixed using sonication for 25
minutes. Similar to the pre-polymer without the model compound, the dye-loaded
solution was transferred to PDMS molds and was synthesized under the same UV-light
for 5 to 15 minutes. The reaction scheme is presented in Appendix A-1.

3.1.3

Polymer Characterization

Four polymers with initial mole ratios of PNA to PETMP and EGDT were synthesized.
The attenuated total reflectance Fourier-Transform Infrared Spectroscopy (ATR-FTIR)
spectra were collected on a Bruker Vector 22 Infrared instrument. Differential Scanning
Calorimetry (DSC) was performed using a DSC Q20 TA instrument. Samples of
approximately 8 mg were placed in an aluminum Tzero pan where they underwent a
heat/cool/heat profile at 10 °C min−1 under nitrogen (N2) atmosphere (50 mL min−1). Data
was obtained from the final heat cycle of the heat/cool/heat profile. Before conducting the
DSC experiments, the variation of the mass of samples was measured using the thermal
gravimetric analysis (TGA) by a TA instrument Q50 TGA instrument under an atmosphere of
N2 while the temperature was changing over time. Samples were put in a platinum pan and
were heated at a rate of 10 °C min–1 under a flow of N2 (60 mL min–1). Water contact angles
(WCAs) were measured by a Kruss DSA100 Drop Shape Analyzer. The WCAs were
measured three times for bottom and three times for the top surface of each polymer, and the
mean of these six measurements was calculated. Synthesized polyanhydrides were evaluated
using the powder x-ray diffraction (PXRD) technique at room temperature. Rigaku-MiniFlex
powder diffractometer (made in Japan) was used to collect PXRD data using Cu Ka (k =
1.54059 Å) over the range of 0o < 2θ < 60o with a step width of 0.02o. The NIH ImageJ
software (version 1.8.0) was used to measure polymer dimensions from photos taken by a
Canon SX201 IS digital camera. The concentration of acid orange 10 in the solution was
calculated using the absorbance measured by either a UV-visible spectrophotometry device
(UV-VIS-NIR Spectrophotometer Shimadzu) or a micro-plate reader (Asys UVM 340)
instrument.
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3.1.4

Fabrication of 3D Printed Master Molds

Polymers with different initial mole ratios of PNA to the PETMP and EGDT were
synthesized in PDMS molds in order to be used for mass loss study. PDMS molds were
fabricated using master molds printed by commercial DLP 3D printer (PICO2, ASIGA).
Desired 3D models were designed by AutoCAD software and printed layer by layer from
an UV-curable resin (Clear 2500T). The layer thickness was set as 250 µm, and the
irradiation time for each layer was 5s. The 3D printed objects were treated using
sonication in ethanol for 10 min and washed by Deionized (DI) water to remove any
uncured polymer.

3.1.5

Polymer Mass Loss

The main focus of this chapter is on studying the mass loss profile of polyanhydrides
synthesized by thiol-ene photopolymerization. Understanding of the mass loss profile is
crucial for determining the erosion rate of the polymer, which is ideally proportional to
the release rate of loaded drugs. The typical mass loss profile of this class of
polyanhydrides is shown in Figure 3-1. This profile can be divided into two parts: the
induction period and the erosion period. When polymers are immersed in the aqueous
media, for a few hours they uptake some water (induction period), then start eroding until
the completion of the polymer mass loss (erosion period).
The mass loss profiles of polymers with different initial mole ratios of PNA to PETMP
and EGDT were studied. Herein, the typical mass loss measurement method used during
this study is described (unless otherwise specified). To obtain the mass loss profile,
polymers were immersed in 5 ml PBS (pH=7.4) in glass vials, before being placed on a
shaker (VWR micro-plate shaker). The shaker was set up at 37 °C with specific shaking
rates (120 rpm). At certain time points (mostly every hour), the polymers were extracted
from the solution, the water on the surface of the polymer was carefully wiped off using
the disposable wipes (Kimwipes), and the dry polymer was weighted using the weight
balance.
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Figure 3-1: Mass loss profile of thiol-ene polyanhydrides for a cylindrical polymeric tablet. The
mass loss profile consists of two main parts: the induction period, and subsequent erosion part.

3.1.5.1

The Effect of Parameters on Mass Loss Profile of Thiol-ene
Polyanhydrides

As discussed in section 2.2.2, there are several parameters affecting the erosion of
polyanhydrides. Various studies have been performed to examine the effect of different
parameters on the erosion behavior of polyanhydrides (see section 2.2.2). Recently, a new
type of polyanhydrides was synthesized using thiol-ene photopolymerization which is
used in this thesis study. To our knowledge, the erosion behavior of this type of
polyanhydrides under different parameters has not yet been studied. An extensive study
on the effect of different parameters on mass loss (erosion) profile of this type of polymer
was performed.
In most of the experiments, the typical mass loss measurement described in section 3.1.5
was used (unless otherwise specified). Briefly, the synthesized cylindrical polymers were
placed into PBS at pH=7.4. For most of the experiments, the dimensions of cylindrical
polymers were 8.7 mm × 8.7 mm (diameter × height). The shaker was set on 120 rpm
and 37 °C to mimic the human gastrointestinal (GI) tract environment. The polymers
were extracted from PBS and weighted at once every hour until the completion of the
polymer mass loss. All experiments were conducted in triplicate. After measuring the
mass of polymers over time, the remaining mass percentage and the fractional mass loss
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percentage were calculated using Equation 3-1 and 3-2 where M0 is the initial mass of the
polymer, and Mt is the polymer mass at time, t.
𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑚𝑎𝑠𝑠 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =

𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =

Mt
× 100,
M0

(3-1)

M0 − Mt
× 100,
M0

(3-2)

The parameters that were evaluated in this study for their effect on the polymer’s mass
loss profile included: the temperature, agitation rate, and pH of the media, as well as the
geometry and the composition of polymers.
To explore the effect of polymer compositions on the mass loss profile, four different
initial mole ratios of PETMP over EGDT (PETMP: EGDT = 100:0, 75:25, 50:50, and
25:75) were used. After synthesizing polymers in cylindrical PDMS molds, experiment
parameters were the same as explained in the previous paragraph, except for the
temperature. This set of experiments was performed at room temperature. The previously
described typical mass loss measurement was conducted for all of the polymers in this set
until the vanishing of the polymers’ mass. In a similar set of experiments, the same
procedures of mass loss measurements were conducted for the three polymers with initial
mole ratios of PETMP: EGDT = 100:0, 75:25, and 50:50, this time at 37 OC. By
comparing the mass loss data obtained from these two sets of experiments, the effect of
temperature on mass loss profiles of polymers was examined.
The emergence of advanced fabrication techniques such as micro-fabrication technology
and 3D printing made the fabrication of tablets with complex geometries easier. The
importance of the tablet geometry on the polymer erosion and drug release can be studied
by designing and fabricating of polymers with complicated geometries. The impact of the
polymer geometry on the mass loss profile was investigated by fabricating several
cylindrical polymers with different diameters and heights. Firstly, polymers made of two
initial mole ratios of PETMP to EGDT of 100:0, and 75:25 were fabricated with diameter
and height both equal to 3.3 mm. After measuring the polymers’ mass loss, the pattern of
the mass loss profiles of the smaller polymers was compared to that of the bigger
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polymers (diameter and height = 8.7 mm). This experiment also answers the question of
whether the induction period and/or the mass-loss rates are affected by the substantial
reduction in the volume of the cylindrical polymers from 𝜋(4.352 × 8.7) to 𝜋 (1.652 ×
3.3) with the same compositions.
Three separate experiments were designed to examine the effect of the polymer surface
area, volume, and surface area to volume (SA/V) ratio on the mass loss profile of the
polymer containing PNA and PETMP monomers (EGDT was not used in this set of
experiments). In the first experiment, two cylindrical polymers with the same surface area
were fabricated, with the volume of one 36% higher than the other. In the second
experiment, the volumes of the two cylinders were kept constant and the surface areas
had a 44 % difference. Finally, two polymers with different surface areas and volumes,
but equal SA/V ratios were fabricated.
Oral tablets experience different pHs through the GI tract, and therefore investigating the
impact of different pHs on erosion behavior of polymers that have potential applications
in oral tablets is of high importance. Five PBS solutions with five different pH values
(2.55, 4.27, 6.09, 7.41, and 7.98) were prepared to mimic the pH of different parts of GI
tract. The mass loss measurement was conducted for polymer cubes (8.7×8.7×8.7mm)
consists of PNA and PETMP monomers at room temperature.
To investigate the effect of the mass transfer (mixing) on polymer mass loss profile, the
polymers synthesized from PNA and PETM monomers were placed at different shaking
rates (0, 60, and 120 rpm). These experiments help us understand the impact of the
velocity of the solution on mass loss of the polymer.
Adding drugs or model compounds changes the composition of the polymer, which can
result in changes in the mass loss profile of polymers. Polymers made of PNA and
PETMP were synthesized with and without the model compound. In the latter case, acid
orange 10, 1wt % was loaded in the polymer which was then synthesized under the UVlight for 15 minutes. The mass loss measurements were conducted for both polymers.
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3.1.5.2

Fitting Mass Loss Data

Several studies have shown that polyanhydrides predominantly undergo surface
erosion1,2. Researchers have shown that the linear mass loss profile of polyanhydrides
results in a near zero-order drug release from these polymers3,4. Most of these studies
used polyanhydrides in the form of a slab (a thin layer of polymer). Using the new type of
polyanhydrides synthesized by thiol-ene photopolymerization, a rectangular slab
(2× 10 × 10 mm) made of PNA and PETMP showed a linear mass loss profile. More
complicated mass loss profiles were observed for a cube made of the same polymer 5. In
this section, the behavior of the mass loss over time was examined. The data collected for
polymeric cylinders and cubes made with mole ratios of PNA: PETMP: EGDT =
100:100:0, 1:0.9:0.1, 1:0.75:0.25, 1:0.5:0.5, and 1:0.25:0.75 were fitted to linear,
quadratic, and cubic equations and the r-squared values were compared to find the bestfitted curve.

3.1.5.3

Release Kinetic Models Fitting

Mathematical modeling is a helpful tool to accelerate the development of pharmaceutical
products. Mathematical models play an important role in understanding the
physicochemical mechanisms governing the advanced CRSs and help with predicting the
drug release rates. Prediction of the profile of drug release from polymers not only
reduces the cost and time associated with experiments but also helps with providing
effective therapies through using a more precise release rate of drugs6.
There are numerous mathematical release kinetic models available for polymeric DDSs
including the mechanistic or phenomenological, empirical, and semi-empirical models.
Mechanistic release models for polymers that are predominantly controlled by diffusion
mechanisms are extensively reviewed by Siepman et al7. Mechanistic models based on
diffusion, dissolution, degradation and erosion mechanisms of polymeric DDSs that have
used for the past 30 years have been reviewed by Fu and Kao et al.8. Various mechanisms
affect the release of drugs from a solid oral dosage form, rendering mechanistic release
modeling very complicated9. In advanced DDSs, various biomaterials with different
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characteristics and complex geometries are employed and therefore current mechanistic
models cannot adequately describe their drug release profiles.
Empirical models are the equation-based mathematical models which are not dependent
on physical or chemical laws. Semi-empirical models are based on empirical models;
however, they can be explained by physical and/or chemical laws under certain
conditions9. Empirical models have been frequently used because of the complexity of
the mechanisms involved in drug release from DDSs. The drug release profile can be
obtained by selecting the suitable model equation and estimating the model parameters
based on experimental data.
There are several release kinetic models available, among which zero-order, first-order,
Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Hofenberg, and Weibull, are the most
commonly used for describing the release profile from polymeric systems10,11. As drug
release rate from surface eroding polyanhydrides follows the polymer mass loss profile
(i.e. it is proportional to the erosion rate of the polymer), release kinetic models fitting on
the mass loss data for thiol-ene polyanhydrides were examined. Zero-order, first-order,
Higuchi, Korsmeyer-Peppas, Hixon-Crowell, Hopfenberg, and Weibull kinetic models
were studied. The mass loss measurements were conducted for polymeric cylinders and
cubes with mole ratios of PNA: PETMP: EGDT = 1:1:0, 1:0.75:0.25, 1:0.5:0.5, and
1:0.25:0.75. Mass loss data were fitted to these seven mathematical models using
MATLAB MathWorks software. The coefficient of correlation R2 and the root mean
squared error (RMSE) were used for verifying the fitting accuracy in order to find the
best-fitted model. Below are brief explanations of each model and how each model is
used to fit the mass loss data.
The zero-order kinetic model describes a release system where the drug is released at a
constant rate regardless of its concentration. Equation 3-3 shows the zero-order release
kinetic model where 𝐶0 is the initial amount of the drug in the solution, 𝐶𝑡 is the total
released drug until time 𝑡, and 𝐾0 is the zero-order rate constant. Most of the transdermal
systems and some tablet matrix systems containing drugs with low solubility are the
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examples of zero-order release kinetics applications12.

Here, the zero-order model

described in Equation 3-3 to the measured cumulative mass released over time is used.
𝐶𝑡 = 𝐶0 − 𝐾0 𝑡

(3-3)

The first-order model describes concentration-dependent release behavior. Equation 3-4
shows the first-order kinetics model where 𝐶𝑡 is the total released drug until time 𝑡, and 𝐾
is the first-order rate constant. Equation 3-4 can be reorganized to another form of firstorder release kinetics model which is shown in Equation 3-5 where 𝐶0 is the initial
concentration of drug in the solution. The main application of this model is for watersoluble drug-loaded dosage forms in porous structures13. The log of the remaining mass
percentage (calculated by Equation 3-1) versus time to the first-order model (Equation 3−𝐾𝑡

4) gives a straight line with a slope of 2.303.
𝑑𝐶𝑡
= −𝐾𝐶
𝑑𝑡
𝑙𝑜𝑔𝐶𝑡 = 𝑙𝑜𝑔𝐶0 −

(3-4)
𝐾𝑡
2.303

(3-5)

The first and most commonly used mathematical model for describing the drug release
rate from matrices have been developed by Higuchi14 in 1961. At first, the model was
only developed for planar systems which was later modified to a more complicated
equation that considers porous polymers in different geometries15. The basic Higuchi
model is shown in Equation 3-6 where 𝐶 is the amount of the drug release per unit area
of the matrix, 𝐷 is the diffusion coefficient for the drug in the matrix, 𝑞𝑡 is the total
amount of drug in a unit volume of matrix, 𝐶𝑆 is the dimensional solubility of drug in the
polymer matrix, and 𝑡 is the time. Higuchi model can be simplified to Equation 3-7,
which relates the cumulative drug release (the total released drug until time 𝑡) to the
square root of time by Higuchi constant (𝐾𝐻 ). The measured cumulative amount of mass
released verses square root of time was fitted to Equation 3-7.
1

𝐶 = [𝐷(2𝑞𝑡 − 𝐶𝑆 )𝐶𝑆 𝑡]2

(3-6)
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1
𝐶𝑡
= 𝐾𝐻 𝑡 2
𝐶∞

(3-7)

The power law is a semi-empirical model that relates drug release with time
exponentially, as described by Equation 3-8. Korsmeyer-Peppas equation16 was
developed in 1983 for drug release from hydrophilic polymers as shown in Equation 3-9
where

𝐶𝑡
𝐶∞

is the drug release fraction at time = 𝑡 , 𝐾 is the rate constant, and n is the

release exponent. By deriving the release exponent 𝑛 (ranging from 0 to 1), the release
mechanism of the polymeric system with certain geometry can be interpreted 17. To find
the release mechanism, the first 60% of mass loss data calculated from Equation 3-2 were
fitted to the Korsmeyer-Peppas model (Equation 3-8).
𝐶𝑡
= 𝐾𝑡 𝑛
𝐶∞

(3-8)

The above equation can also be written as:
𝑙𝑜𝑔

𝐶𝑡
= 𝑙𝑜𝑔𝐾 + 𝑛 𝑙𝑜𝑔 𝑡
𝐶∞

(3-9)

In 1931, Hixson-Crowell model was developed18 with the argument that the surface area
of a group of particles is proportional to the cubic root of their volume. Equation 3-10
describes their model. 𝐶0 is the initial amount of the drug, 𝐶𝑡 is the total amount of the
drug released by time t, and 𝐾𝐻𝐶 is the Hixson-Crowell rate constant. This model
describes the systems in which the surface area and diameter of particles or tablets
change over time. In this study, the measured remaining mass percentage versus cubic
root of time was fitted to the Hixson-Crowell model.
1

1

𝐶0 3 − 𝐶𝑡 3 = 𝐾𝐻𝐶 𝑡

(3-10)

Hopfenberg model describes drug release from erodible systems with different
geometries. In Hopfenberg model, the release rate is proportional to the surface area of
the system. Equation 3-11 shows the Hopfenberg empirical equation where 𝐶∞ is the
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initial amount of drug-loaded in the system, 𝐶𝑡 is the amount of drug released at time 𝑡,
𝐾0 is the rate constant of surface erosion process, 𝑎 is the half-thickness (half-thickness
in case of slab or radius in case of cylinders or spheres), 𝐶𝑙 is the initial drug
concentration in the system, and 𝑛 is the release exponent (𝑛 = 1 for slab, 𝑛 = 2 for
cylindrical, and 𝑛 = 3 for spherical geometries)

19

. In this study, the fractional mass

release (mass loss) versus time was fitted to Hopfenberg model with 𝑛 = 1 for cubic and
𝑛 = 2 for cylindrical tablets.
𝐶𝑡
𝐾0 𝑡 𝑛
= 1 − [1 −
]
𝐶∞
𝐶𝑙 𝑎

(3-11)

The Weibull kinetic model is another empirical model which can be used for dissolution
and releasing drugs from oral dosage forms20. Weibull model is shown in Equation 3-12
where 𝐶0 is the total amount of drug released, 𝐶 is the amount of the drug dissolved at
time 𝑡, 𝑇 is the lag time, 𝑎 is the scale parameter, and 𝑏 is the release curve shape. The
fractional mass release (mass loss) verses time were fitted to Weibull model (Equation 312).

𝐶 = 𝐶0 [1 −

−(𝑡−𝑇)𝑏
𝑒 𝑎 ]

(3-12)

Table 3-1 summarizes all the above-mentioned release kinetic models’ equations with a
brief description of their release mechanisms.
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Table 3-1: Release kinetic mathematical models 12,21–23.

Model

Mathematical Equation

Release Mechanism

Zero order

𝐶 = 𝐶0 − 𝐾0 𝑡

Diffusion mechanism

First Order

𝑙𝑜𝑔𝐶 = 𝑙𝑜𝑔𝐶0 −

𝐾𝑡
2.303

Diffusion mechanism
Fick’s first law

1

𝐶 = [𝐷(2𝑞𝑡 − 𝐶𝑆 )𝐶𝑆 𝑡]2
or
1
𝐶𝑡
= 𝐾𝐻 𝑡 2
𝐶∞

Higuchi

Korsmeyer-Peppas

𝑙𝑜𝑔

Power Law

𝐶𝑡
= 𝑙𝑜𝑔𝐾 + 𝑛 𝑙𝑜𝑔𝑡
𝐶∞
𝐶𝑡
= 𝐾𝑡 𝑛
𝐶∞
1

1

Diffusion-based mechanism
Fick’s first law

Semi empirical model
Diffusion mechanism

Hixson-Crowell

𝐶0 3 − 𝐶𝑡 3 = 𝐾𝐻𝐶 𝑡

Erosion mechanism
Mechanistic model

Hopfenberg

𝐶𝑡
𝐾0 𝑡 𝑛
= 1 − [1 −
]
𝐶∞
𝐶𝑙 𝑎

Erosion mechanism
Empirical and mechanistic
model

𝐶 = 𝐶0 [1 − 𝑒

Weibull

3.2

−(𝑡−𝑇)𝑏
𝑎
]

Empirical model
Life-time distribution
function

Results and Discussion

This section presents and discusses the results of the experiments conducted for studying
the

mass

loss

profile

of

the

polyanhydrides

synthesized

using

photopolymerization as well as the results for kinetic models fitting study.

thiol-ene
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3.2.1

Polymer Preparation and Characterization

Cross-linked polyanhydrides were synthesized using thiol-ene photopolymerization
reaction. ATR-FTIR results showed the absence of thiol and vinyl peaks at 2565 cm-1 and
1640-1650 cm-1, respectively. It also specified the dual peaks of anhydride functional
groups at 1730-1740 cm-1. These peaks indicate that almost all the thiol and vinyl
functional groups were reacted. The FTIR spectra, which is shown in Appendix A-2 is in
agreement with the FTIR data obtained by Rutherglen et al.24 for the same polymers.
PXRD was used to show the crystallinity of polymers. PXRD data (Figure 3-2) for all
synthesized polymers demonstrated the amorphous domains of the polymers’ structure.
Amorphous polymers do not contain the periodically arranged atoms, unlike the
crystalline polymers. In amorphous structures with atoms distributed randomly, the X-ray
scatters in different directions, resulting in a large bump in the FTIR spectrum in a wide
range (2θ). In contrast, in crystalline structures, there are sharp peaks with high intensity
which are narrow at some points (periodically arranged atoms result in scattered X-ray in
certain directions)25. Semi-crystalline structures have both the large bump and narrow
peaks in their PXRD pattern such as the semi-crystalline polyanhydrides synthesized by
Poetz et al.26. The XRD results indicate the same large bumps without any sharp peaks
with high intensity for all polymers, showing their amorphous domains.
TGA studies demonstrated that synthesized polyanhydrides (PNA: PETMP: EGDT =
100:100:0, 100:75:25, 100:50:50, 100:25:75), had thermal stability with the onset of
decomposition observed at 329 °C, 328 °C, 324 °C, and 317 °C respectively (Appendix
A-3). High stability of the samples allowed conducting DSC experiments. DSC was
conducted to obtain the glass transition temperature (Tg) of each polymer. Tg values
were specified from the second cycle of heat/cool steps to be -25.1°C, -36.6°C, -48.9°C,
and -55.8°C respectively which are similar to Tg values previously reported using
dynamic mechanical analysis (DMA)24. Besides, DSC results did not display any
crystalline melt temperature (Tm), which confirmed the results of PXRD regarding the
amorphousness of the polymers’ domains (Appendix A-4).
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Figure 3-2: PXRD patterns of four thiol-ene polyanhydrides.

Hydrophobicity of four polymers (PNA: PETMP: EGDT = 100:100:0, 100:75:25,
100:50:50, 100:25:75) was also evaluated using the water contact angle measurement.
The angle between the water droplet and the top and bottom surfaces of the synthesized
polymers were measured three times for each side of the surface. The mean of the six
measurements for each polymer was calculated to be 81.8° ± 4.8, 72.0° ± 7.0, 68.5°± 8.5,
and 63.5° ± 7.3, respectively. A water contact angle smaller than 90o shows a relative
hydrophilic solid surface whereas angles higher than 90o show a hydrophobic surface. A
decrease in the water contact angle values is observed with increased EGDT to PETMP
initial mole ratios. The reason is known to be the higher cross-link density of polymers
with higher initial mole ratios of PETMP

24

. The range of the measured water contact

angles (from 64° to 82°) is in agreement with other surface-erodible polymers27 and
polyanhydrides in particular28.

3.2.2

Polymer Mass Loss Profile

In this section, the impact of various parameters on the mass loss profile of thiol-ene
polyanhydrides is investigated.
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3.2.2.1

The Impact of Polymer Composition

The remaining mass percentage (Figure 3-3A), as well as the fractional mass loss
percentage (Figure 3-3B) were plotted for all four polymers. Mass loss profiles showed
approximately 10 hours of induction period, which is in close agreement with the results
obtained by Ship et al.29 for the same polymers. Total erosion times ranged from 20h to
50h. Figure 3A indicates that an increased initial mole ratio of EGDT results in a shorter
total erosion time. Figure 3B also indicates faster erosion rates for polymers with higher
mole ratios of EGDT against PETMP in their networks. However, induction periods did
not change by changing the polymer composition using different mole ratios of
monomers.
The primary reason for differences in erosion rates is known to be the cross-linking
density of polymers. The cross-linking density decreases with an increased ratio of
EGDT26. Another reason could be the crystallinity of the polymers since, as discussed in
section 2.2.3, polyanhydrides with higher crystallinity show lower erosion rates than
polyanhydrides with amorphous domains26,30. PXRD and DSC were used to evaluate the
level of the crystallinity of four polymers. As explained in section 3.2.1, PXRD data
displayed the amorphous domains for these polymers, and DSC data did not show any
Tm, that confirms the lack of the crystallinity in their structures. Water contact angles
were also measured to obtain the relative hydrophobicity of polymers as another potential
reason for different erosion rates observed in mass loss profiles of our four different
polymers. Results for water contact angles measurements are discussed in detail in
section 3.2.2.1. Table 3-2 summarizes the results of experiments performed to explore the
reasons behind different erosion rates of different polymer compositions as well as the
cross-link density of polymers obtained from Ref26.
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Figure 3-3: The impact of polymer compositions on mass loss profiles. A) Remaining mass
percentage and B) Fractional mass loss percentage of thiol-ene based polyanhydrides. Increasing
the EGDT in polymer networks leads to faster erosion rates. However, changing the mole ratios
of EGDT over PETMP did not change the induction periods.
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Table 3-2: Properties of polymers obtained from experiments for exploring
reasons for the change in erosion rates of different compositions of polymers.

3.2.2.2

The Effect of Temperature

The reactions occurring between polymer bonds in contact with the aqueous media drive
degradation of biodegradable polymers. Temperature can change the reaction rates and
consequently change the erosion rate of polymers. The impact of temperature on
polymers’ mass loss profiles was investigated by measuring the mass loss of polymers in
PBS set at two different temperatures (the ambient temperature (25°C) and the
physiological temperature (37°C)). Figure 3-4 compares the results by showing the mass
loss data for polymers at the two temperatures. The induction period was reduced from
approximately 10 hours to 5 hours at a higher temperature for all polymers. Erosion rates
were considerably higher at PBS with 37°C in comparison to the room temperature
environment. The acceleration of degradation rates by elevation of the temperature for
biodegradable polymers such as PLA and PLGA have reported in several studies 31–33.
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Figure 3-4: The impact of temperature on polymer mass loss profile. The remaining mass
percentage of A) Four polymer compositions at room temperature. B) Three polymer
compositions at 37°C. Higher temperature leads to shorter induction periods and shorter erosion
times.

3.2.2.3

The Effect of Tablet Geometry

First, the mass loss data for two small cylindrical polymers were compared to the mass
loss of the larger polymers with the same compositions. Results show a similar induction
period (~5hours) for smaller polymers compared to the larger ones (Figure 3-4). The
total erosion times for the smaller and larger polymers reduced from 17h to 13h and 9h to
6.5h when PETMP: EGDT = 100:0 was changed to PETMP: EGDT = 75:25,
respectively. The reason for shorter total erosion times for the smaller tablets is their
reduced mass, which erodes entirely in a shorter time. Results of a study conducted by
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Akbari et al. show similar changes to the induction periods and mass loss rates when the
effect of different geometries of p(CPP:SA) on mass loss profiles was examined34.
Similar patterns of the mass loss profile observed for both tablet geometries in our study
confirms that thiol-ene polyanhydrides’ maintain their surface erosion behavior even at
very small sizes. This observation agrees with previous findings regarding the very small
critical device dimension value for polyanhydrides (discussed in section 2.1.3.4)4. Results
indicate the high potential of this type of polyanhydrides to be used for various
applications that require small size DDSs such as mini-tablets to benefit pediatric
patients35.
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Figure 3-5: Impact of tablet geometry. The remaining mass percentage for bigger cylindrical
tablets (diameter and height equal to 8.7mm) (A) and smaller cylindrical tablets (diameter and
height equal to 3.3mm) (B).

The effect of the tablet surface area, volume, and SA/V ratio on the mass loss rates and
induction periods of two cylindrical tablets with the same polymer compositions was also
studied. The induction periods for the tablets with the same surface areas and different
volumes were similar (~5hours), while the total erosion time for the tablet with lower
volume was shorter. The reason is that the mass of the smaller volume tablet is less than
the other tablet. Although both tablets had similar induction periods, the cylindrical
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polymer with higher volume has taken longer to erode, with a slower remaining mass loss
percentage rate as shown in Figure 3-6.

Figure 3-6: Impact of geometry on the mass loss profile of polymers. A) Remaining mass
percentage of two tablets with the same surface areas and different volumes (V1 = 1.36 V2). B)
Schematics of tablet designs and dimensions.

To explore the effect of the surface area on mass loss profiles, two cylindrical tablets
were designed and fabricated with same volumes but different surface areas. The mass
loss data for both tablets show similar induction periods; however, the mass-loss rate for
the tablet with 44% higher surface area is faster. Although in this case the total mass of
both tablets was initially the same, the tablet with a higher surface area exposed to PBS,
showed faster mass loss rate and consequently higher erosion rate (Figure 3-7). Results
show that the same total amount of drugs can be delivered at different rates by changing
the surface areas of the tablet and keeping the volumes constant.
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Figure 3-7: Impact of geometry on the mass loss profile of polymers. A) Remaining mass
percentage of two tablets with the same volumes and different surface areas. B) Schematics of
tablet designs and dimensions.

Finally, two tablets with different surface areas and volumes were fabricated. For both
tablets, the SA/V ratio was equal to 0.69. Although one of the tablets (the orange tablet in
Figure 3-7 B) had a higher surface area and higher total volume, the mass loss data of
both tablets closely follow each other as shown in Figure 3-8A with similar mass loss
percentage rates. In addition, no change is observed in induction periods of the two
tablets.
Results show the importance of the SA/V ratio of the tablet for determining the mass loss
percentage rates of polymers. The induction period was not affected by the tablet
geometries, while the mass-loss rate for a polymer with higher surface area and lower
volume was shown to be faster. Polymers with the same SA/V ratios showed similar
mass loss percentage rates despite the higher volume and larger surface area of one tablet
against the other. Recently, the importance of the SA/V ratio of tablets has been studied
by researchers, and their results agree with our findings. For example, Goyans et al.
showed that the fractional drug release from an erosion mediated controlled-release
tablet, made of PVA filaments, is only dependent on the SA/V ratio rather than the
surface area or the volume separately36. Martinez et al. performed a dissolution test on
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various tablet geometries with the same SA/V ratios. Tablets with similar SA/V ratios
resulted in a similar fractional drug release rate, while tablets with same surface areas
showed different fractional release rates. They also showed an increase in dissolution
rates of tablets by increasing the SA/V ratio of tablets, which were made of polyethylene
glycol diacrylate (PEGda)

37

. The similar results have been obtained for a controlled-

release tablet made of hydroxypropylmethylcellulose (HPMC)38.

Figure 3-8: Impact of geometry on the mass loss profile of polymer. A) Remaining mass
percentage of two tablets with the same SA/V ratio while both surface areas and volumes are
different. B) Schematics of tablet designs and dimensions.

3.2.2.4

The Effect of pH

Oral tablets reside in different parts of the GI tract for specific time intervals at various
pHs ranging from 1-2.5 at the stomach to 7.88 at the distal small intestine (Figure 3-9A).
Therefore, the effect of pH on mass loss profile of a thiol-ene polyanhydride made of
PNA and PETMP was studied. The induction periods and mass loss rates were similar for
all samples except for the one in pH=7.89, which showed shorter induction period and
faster mass loss rate. The faster mass loss rate of the polymer in alkaline solution is in
close agreement with studies that showed acceleration in degradation of biodegradable
polymers in more alkaline environment39,40. Considering the induction period that lasts a
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few hours and based on the mass loss data obtained from different pHs, it can be assumed
that a tablet made of this polymer will pass the parts of the GI tract with acidic
environment, and will reside in pHs around 7 while eroding.

Figure 3-9: Impact of pHs on mass loss profile of polymers. A) Schematic representation of GI
tract pathway with various pHs. Reproduced from Ref

41

with permission. B) Remaining mass

percentage of polymers in provided solutions with different pHs.

3.2.2.5

The Effect of Mass Transfer

To explore the effect of mass transfer on the polymer mass loss profile, various shaking
rates were used. Different shaking rates create different convective forces in PBS that can
change the reaction rates by carrying the detached monomers away from the polymeric
tablets. The induction periods and erosion rates stayed similar, with a slightly slower
erosion rate at 0 rpm shaking rate (Figure 3-10). These findings indicate the nonsignificant effect of shaking rates on polymer mass loss profile. Shieh et al.42 found a
similar trend in their study on p(FDA:SA) polyanhydrides.
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Figure 3-10: Mass transfer effect on the polymer mass loss profile. Different shaking rates (0,
60, 120 rpm) were used.

3.2.2.6

The Effect of adding a Model Compound

Adding drugs to the polymer change some physicochemical properties of polymers that
may cause changes in polymer degradation. The polymer and the dye-loaded polymer are
shown in Figure 3-11. Results of the mass loss for the two tablets indicate no
considerable differences in the induction periods and the mass loss rates (Figure 3-11).
During the final five hours of the erosion period, the polymer containing the model
compound eroded very fast (see the orange line in Figure 3-11). This is potentially due to
the presence of uncross-linked monomers in the center of the dye-loaded polymer that
indicates a reduction in the penetration depth of the UV-light in the dye-loaded polymer.
To obtain the same behavior for the dye-loaded polymer as the other polymer, the
polymer loaded with dye should be put under the UV-light for longer times, or at higher
intensities.
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Figure 3-11: Effect of adding the model compound to the polymer on mass loss profile.

3.2.2.7

Pre-Erosion for Eliminating the Induction Period

The induction period (or lag time) during which polymer only absorbs some water lowers
the predictability of the polymer mass loss and therefore is undesired. In addition, for
treating some diseases, the drug needs to start releasing as soon as the patient swallows
the tablet. For eliminating the induction period, a pre-erosion experiment was performed.
The cylindrical polymers made of initial mole ratios of PNA: PETMP: EGDT =
100:75:25 were immersed in PBS for 8 hours. The polymers were extracted from the
solution after the induction period and when the erosion had been started and were put
under the vacuum for 10 hours. After 10 hours, the polymers were again placed in PBS
and the mass loss measurements were carried out. Figure 3-12 indicates how the mass
loss of the samples after pre-erosion follows the mass loss profile of the samples that
were not pre-eroded. This finding shows that the induction period can be removed for this
polymer by means of the pre-erosion process. Langer group studied the elimination of the
lag time for Poly[bis(p-carboxyphenoxy)methane (PCPM) polyanhydride by pre-eroding
it for 50 hours at 60 °C 43.
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Results for pre-erosion experiments showed that when the polymer is placed in PBS
again, after pre-erosion and vacuuming, the polymer continues the erosion from where it
left off, instead of undergoing a second induction period. This can be attributed to a
decrease in the hydrophobicity of the polymer surface due to hydrolysis when it is in
contact with PBS in the pre-erosion period. This experiment was a proof of concept for
the feasibility of eliminating the induction period for thiol-ene polyanhydrides. Further
experiments should be designed and performed to further investigate the elimination of
the induction period using the mentioned pre-erosion process.

Figure 3-12: The pre-erosion process to eliminate the induction period.

3.2.2.8

Fitting Mass Loss Data

The mass loss data collected for cuboid and cylindrical polymers were used for fitting
with the linear, quadratic, and cubic polynomials. The collected data during the erosion
period were used since there are no considerable changes during the induction period to
be evaluated. Mass loss data were fitted to the functions using Microsoft Excel and the R2
for each fit was calculated for two of the polymers (Figure 3-13). The results of curve
fitting for other cuboid and cylindrical polymers are shown in Appendix B-1 and B-2.
Table 3-3 summarizes the mathematical equations and the R2 values of each fit to the
mass loss data for a cuboid and a cylindrical polymer. Although polyanhydrides are well

75

known for their near-linear mass loss, the linear equation does not describe the mass loss
data very well, as also indicated by lower R2. The best fit for both the cylindrical and
cuboid polymers mass loss data is the cubic equation because of the slightly higher R2
values in comparison to quadratic functions.

Figure 3-13: Fitting mass loss data for two cylindrical polymers with initial mole ratios of
PETMP: EGDT = 100:0 and 50:50. The linear, quadratic, and cubic fits and their R2 show that the
best fit is the cubic function.
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Table 3-3: Mass loss data fitting. Linear, quadratic, and cubic polynomials were fitted to the
mass loss data of four polymers with different compositions of monomers in two different shapes.

3.2.3

Release Kinetic Models Fitting

The curve fitting toolbox of MATLAB R2016 was used to fit the mass loss data to the
above-mentioned equations mentioned in Table 3-1. A model with the highest R2
(correlation coefficient closest to 1) and the minimum RMSE (equal to highest
concentrated data around the line of fit) were considered as the best fitted model. The
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regression coefficient, R2, and the best-fit model parameters are reported. Figure 3-14
shows the selected models and their corresponding R2 values. According to Table 3-4 that
summarizes results for cylindrical systems, the best fit was obtained using the
Hopfenberg and Hixson-Crowell models for the polymer compositions used in our tablet
fabrication (PETMP: EGDT = 100:0, 75:25). The same study was conducted for the data
collected for the cuboid polymers. Figure 3-15 shows some of the experimental data and
their fitted curves. Table 3-5 summarizes the results for the polymer cubes. The HixsonCrowell and Weibull models yield the best fit for the cuboid polymeric system mass loss
data points.
Based on the best-fitted models, both cylindrical and cubic systems obeyed the HixsonCrowell and Hopfenberg models, which describe polymers with erosion mechanisms
rather than diffusion-controlled systems. This study, mathematically proved that the
fabricated polymeric systems undergo surface erosion, which has been shown before
experimentally29. While finding the best fit models, the parameters of each release kinetic
models were derived and summarized in Table 3-4 and 3-5. Using these parameters, the
release of the drug through these polymers can be predicted. The results of curve fitting
to other models can be found in Appendix C1-5 for both cylindrical and cuboid polymers.
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Figure 3-14: Selected some of the best fitted kinetic models for cylindrical tablets.
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Table 3-4: Release kinetic models fitting for a cylindrical system. The models with their
equations, mole ratios of monomers, R2, and derived parameters are shown in this table.
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Figure 3-15: Selected best fitted kinetic models for cuboid polymers.
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Table 3-5: Release kinetic models fitting for cuboid polymers. The models with their equations,
mole ratios of monomers, R2, and derived parameters are shown in this table.
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Chapter 4
High-throughput Fabrication of Drug-loaded Core-shell
Tablets for Personalized Medicine

4

In this chapter, a high-throughput platform is developed for fabricating drug-loaded
tablets. The tablets, achieved using a novel tablet design, have adjustable release rates.

4.1

Materials and Methods

This section details the materials used in this study and describes the methodology used
for designing and manufacturing the drug-loaded polymeric tablets with adjustable
release profiles.

4.1.1

Materials

4-Pentenoic anhydride (PNA), 2, 2-(Ethylenedioxy)diethanethiol (3,6-Dioxa-1,8-octanedithiol,

EGDT),

Pentaerythritol

tetrakis(3-mercaptopropionate)

(PETMP),

1-

Hydroxycyclohexyl phenyl ketone, Trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane and
acid orange 10 (orange G) were purchased from Sigma Aldrich Chemical Co. and were
used as received. SU-8 2050 photoresist was purchased from MicroChem Corporation.
3D printer acrylate-based resin (Clear 2005T) was purchased from MiiCraft. Both the
Sylgard 184 Silicone Elastomer pre-polymer and the curing agent were purchased from
Ellsworth Adhesive Chemical Co., and were used for making PDMS. 3.3 mm poly
(methylmethacrylate) sheets (PMMA) were purchased from McMaster-Carr. Tyfon
Microbore tubing (ID 0.079 in) was purchased from Cole-Parmer, Inc.

4.1.2

Polymer Synthesis Procedure

1-Hydroxycyclohexyl phenyl ketone (photo-initiator, 0.1wt %) was weighed and placed
into a 15 ml Falcon tube. Then, PNA was transferred into the tube, followed by the
mixture of EGDT and PETMP.

The solution was mixed to obtain a homogenous

mixture. The initial mole ratio of PNA to the total amount of monomers containing thiol
groups (EGDT and PETMP) was 100:100. In this study, four different initial mole ratios
of PNA to PETMP and EGDT were prepared and used including PNA: PETMP: EGDT =
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100:100:0, 100:75:25, 100:50:50, and 100:25:75. The homogenous pre-polymer solution
was then purged under the inert gas (nitrogen or argon) for 3 minutes and was transferred
to PDMS molds. PDMS molds with different designs and geometries were fabricated and
used according to the desired final geometry of each polymer (see section 4.1.3 for
information on molds fabrication). The pre-polymer solution in molds was exposed to
UV-light (CL-1000 UVP Cross-linker) equipped with 365 nm UV lamps (intensity=~5
mW/cm2) for 5 minutes. To study the release profiles of dye-loaded tablets, a model
compound (acid orange) was added to the pre-polymer solution of some of the tablets.
Acid orange 10 (1-3wt %) was weighed and added to the purged solution and mixed
using sonication for 25 minutes. Similar to the pre-polymer without the model compound,
the dye-loaded solution was transferred to PDMS molds and was synthesized under the
same UV light for 5 to 15 minutes. The reaction scheme is presented in Appendix A-1.

4.1.3

Fabrication of 3D Printed Master Molds

3D printer master molds were used to fabricate the PDMS molds in which the prepolymer solutions were polymerized. The master molds were printed by a commercial
DLP 3D printer (PICO2, ASIGA). Desired 3D models were designed by AutoCAD
software and were printed layer by layer from a UV-curable resin (Clear 2500T). The
layer thickness was set to 250 µm, and the irradiation time for each layer was 5s. The 3D
printed objects were treated using sonication in ethanol for 10 min and washed by
Deionized (DI) water to remove any uncured polymer.

4.1.4

Tablet Design

The tablet has two main parts: the core and the shell (Figure 4-1A). The core is made of a
surface eroding polymer loaded with a drug (shown in orange in Figure 4-1) while the
same polymer without any drug is used for the shell (the grey parts in Figure 4-1). The
core is enclosed by the shell and is placed closer to the top surface compared to the other
faces. When the thickness of the shell is “large enough” for all sides except the top, the
release of the drug only from the top surface of the tablet is ensured (Figure 4-1B). This
design relies on the surface eroding behavior of the polymer which preserves the tablet
structure and integrity during erosion and ensures that the polymer erodes at a similar rate
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from all sides. An experiment was conducted that verified the latter (section 4.1.5).
Therefore, in this design the water first reaches the drug at the top. As the thickness of the
shell is large enough, the drug will be released completely from the top before the water
reaches it from the other sides. Accordingly, the release profile of the drug is only
governed by the variations in the surface area of the drug-loaded core along with its
height (Figure 4-1C). As an example, in Figure 4.1, the surface area of the tablet core
from the top is increasing along its height, showing that this tablet is designed for
obtaining an increasing release profile (Figure 4-1D).

Figure 4-1: Schematic illustrations of core-shell tablet design for an “increasing” release profile.
The core is shown in orange, and the shell is the grey part. A) 3D view and B) front view showing
that the core is closest to the top surface. The shell is made of the same polymer, with larger
thickness than the core’s height on the other sides. C) Release of the drug-containing part when
the tablet is immersed in PBS. D) The expected release profile of the drug for this tablet design.
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4.1.5

Tablet Characterization: Height and Diameter Reduction
Rates

To ensure that the polymer erodes at similar rates from all sides, the erosion of cylindrical
thiol-ene polyanhydrides was studied. Four thiol-ene polyanhydride cylinders with initial
mole ratios of 100:100:0, 100:75:25, 100:50:50, and 100:25:75 were synthesized in
cylindrical PDMS molds. The PDMS molds were fabricated using 3D printed master
molds with the diameter and height both equal to 8.7mm. The synthesized polymers
(cylindrical tablets) were immersed in 10 ml PBS (pH=7.4) in glass vials, before being
placed on a shaker (VWR micro-plate shaker). The shaker was set up at room
temperature and the shaking rate of 120 rpm. The diameter and height of the tablets were
measured frequently (approximately one every hour) during erosion. For each
measurement, tablets were removed from the solution and their surfaces were slowly
wiped off using disposable wipers. The dried tablets were then put on a printed coloured
graph paper, and the photos were taken using a Canon SX201 IS digital camera from four
different sides of each tablet, before putting the tablet back in PBS. Images from the top
and bottom of the tablet were used to monitor the diameter reduction, while the two
images from the sides provided information on variations in the tablet’s height. The NIH
ImageJ software (version 1.8.0) was used to measure tablet dimensions from photos taken.
Experiments were repeated three times for each polymer.

4.1.6

Micro-fabrication of the Tablet Core

A microfluidic network that was fabricated using the conventional standard photo- and
soft-lithography techniques1,2 was utilized to create the dye-loaded polymers used as the
core of the tablets. Steps are shown in Figure 4-2 starting from using a silicon wafer as a
substrate. The SU-8 photoresist was poured on a four-inch silicon wafer, and a 300 μmthick layer of photoresist was spin-coated (Laurell Tech Corp.) on the top surface of the
silicon substrate. Considering the photo- and soft-lithography procedure for microfabrication, a photo-mask that replicated the final desired shape is used. In the design for
the core of the tablet, instead of using the shape of a single tablet core for the photomask, a high-throughput pattern of tablet cores was designed using AutoCAD software
which was then printed as the photo-mask on a high-transparent sheet (Figure 4-2A). The
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SU-8 photoresist (with the desired thickness spin-coated on the substrate) was covered by
the photo-mask and was exposed to high-intensity UV-light (AB-M Inc.) for 80 seconds.
When using a photo-mask, the UV-light only passes through the UV-transparent parts,
crosslinking only the desired areas on SU-8. Therefore, the SU-8 photoresist polymer
hardened only at the designed pattern and the other parts remained uncross-linked. Lastly,
SU-8 developer was used to remove the uncross-linked photoresist from the wafer,
yielding the final SU-8 mold (Figure 4-2B).

Figure 4-2: Schematic illustrations of the micro-fabrication procedure to create the SU-8 mold.
A) Coating the SU-8 photoresist on top of the silicon wafer and putting the printed photo-mask
containing the designed patterns on top of the SU-8-coated silicon substrate. B) Exposure of the
substrate to the UV light in order to cross-link specific parts and then washing away the uncrosslinked parts using the SU-8 developer.

Figure 4-3 shows an example of the design for high-throughput manufacturing of the
tablet core for an increasing release profile. First, the SU-8 master molds were fabricated
using the above-mentioned steps (Figure 4-3 A, B). To fabricate the microfluidic device,
the PDMS polymer mixture containing the 1:10 ratio of the base to curing agent was
thoroughly mixed. To eliminate the trapped air bubbles created in the PDMS sample, the
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mixture was degassed in a vacuum chamber for 15 minutes. As shown in Figure 4-3C,
the negative PDMS mold is developed and peeled off from the SU-8 positive mold. To
facilitate the peel-off process, the SU-8 mold was silanized to make the mold’s
micrometer-sized channels more hydrophobic. The positive SU-8 mold was silanized
using (tridecafluoro-1,1,2,2- tetrahydrooctyl) trichloro silane by putting the mold in a
sealed petri-dish on a hot plate for 2 hours at 65°C. To make the PDMS replica mold, the
mixture was poured on top of the SU-8 mold and were cured in an oven for 2 hours at 80
°C. Finally, the cured PDMS was easily peeled off from the SU-8 master mold, yielding
the high-throughput patterns connected through the microfluidic network (Figure 4-3 C).

Figure 4-3: Micro-fabrication of a high-throughput design to create the tablet core. A) UV-light
exposure to the SU-8 layer covered with the printed photo-mask containing the high-throughput
patterns of the tablet core (in this case, the increasing release profile design). B) The positive SU8 mold containing the embossed features. C) Pouring the PDMS on top of the SU-8 mold and
peeling off the final negative PDMS mold once cured in the oven.
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A platform for using the fabricated PDMS negative molds to make the polymeric tablet
cores was designed (Figure 4-4). Another PDMS negative mold with a pattern mirrored
to that of the original was fabricated and placed on top of the original PDMS negative
mold, making a microfluidic network with 600 µm in thickness for the channels. The top
PDMS negative mold was punched on two sides with a 2 mm biopsy punch (EMS-Core
Sampling Tools) to create inlet/outlet ports through which solutions can flow in the
channels created by the two PDMS negative molds (Figure 4-4). The two PDMS layers
were sandwiched between two rigid PMMA sheets (3.3 mm thickness). Uniformly
distributed holes were designed using AutoCAD software and were cut on PMMA sheets
using the CO2 laser (SUNCOO K40 laser cutter). These holes were designed for using
screw-nuts through which a uniform force was applied to squeeze two PDMS layers
together to prevent any leakage of solutions. At the center of the top PMMA sheet, a
pattern was cut using the laser cutter to allow exposure of the solution in the PDMS
layers to UV-light (Figure 4-4) for curing the tablet cores.

Figure 4-4: Two PDMS layers sandwiched by two rigid PMMA sheets equipped with holes
designed to embed screw-nuts for applying uniform forces on PDMS layers. Squeezing two
PDMS layers using the uniform forces, eliminates the potential leakage of the solutions through
microfluidic channels.
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4.1.7

High-throughput Setup for Fabrication of Core-Shell Tablets

Pre-polymer solutions were prepared as described in the polymer synthesis section. In
this study, two pre-polymer solutions with initial mole ratios of PNA: PETMP: EGDT =
100:100:0, and 100:75:25 were prepared. Approximately 5 ml of solutions containing 1
wt% of acid orange 10 (orange G) model compound were transferred into a vial. The
solution was continuously injected into the microfluidic network from the inlet port using
the Tygon Microbore tubing (0.79″ID) (Figure 4-5A). A vacuum pump was connected to
the outlet, helping draw the solution to fill the champers. After the solution filled the
chambers completely, the features were exposed to UV-light (UVP Crosslinker, intensity
= ~5mW/cm2) for 5 minutes. The screws were then opened and the three connected dyeloaded tablet cores were peeled off by separating the two PDMS layers.
The cured micro-fabricated features (the three connected tablet cores) were then placed in
cylindrical PDMS wells (Figure 4-5B) fabricated using master molds printed by
commercial DLP 3D printer. The procedures for the fabrication of the 3D printed master
molds were the same as the steps described in section 4.1.3. The 3D model of the wells
was designed so that when the high-throughput micro-fabricated cores are placed in the
wells, each of the cores stay at the center (from the sides, horizontally) and at a predetermined distance from the bottom and the top of the well (vertical alignment).
Particularly, as explained in section 4.1.4, the cores were closest to the top and far
enough from all other sides of the wells. After placing the dye-loaded cores in the wells,
the empty spaces around the polymers inside the wells were filled using the same prepolymer solution as the core but without any model compound. Another 5 minutes of
UV-exposure was conducted to cure the newly added polymer solution. Finally, three
tablets were peeled off from the PDMS wells (Figure 4-5B) and simply were separated
using a blade by cutting the connecting part. To allow reusing the PDMS molds, the
channels were washed after peeling off the dye-loaded polymer using the mixture of
water and ethanol. After washing the channels carefully, they were dried using highpressure air for 2 minutes that also ensures cleaning the molds from dirt and possible
residues.

93

Figure 4-5: Schematic representations for the high-throughput fabrication of the core-shell
tablet using A) A high-throughput set up to manufacture the tablet cores. Microfluidic channels
were filled by a dye-containing polymer solution that was injected from a reservoir. The vacuum
pump helps the solution flow through the network. The first round of the UV-light exposure was
used to cure the connected features. B) Micro-fabricated features were placed and aligned in
PDMS wells. Empty spaces were filled with the same polymer without any dye. Using the second
round of UV-light exposure, the final tablets were fabricated.

4.1.8

Tablets for Achieving Adjustable Release Profiles

The ultimate goal of this study is to achieve different release profiles through a novel
tablet design fabricated by a high-throughput fabrication platform. To meet this goal,
different tablet geometries were designed using AutoCAD software. Figure 4-6 indicates
the design of the high-throughput tablet cores which are connected to each other. These
tablet cores were designed for the increasing (Figure 4-6A), and the constant release
profiles (Figure 4-6B). The width of the tablet cores design is increasing and uniform
from the top along their heights in the increasing and constant tablets, respectively.
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Figure 4-6C shows a different design for the core of tablets with constant release profiles
that have two, three, or four constant release cores in each connected feature (this design
will be described in details in the next section). These designs were printed as photomasks and went through soft-lithography steps for making the PDMS molds containing
connected features as a microfluidic network.

Figure 4-6: High-throughput CAD designs for A) Increasing release profile tablet core. B)
Constant release profile tablet core (one-arm design). C) Constant release profile tablet core (twoarm, three-arm, and four –arm designs).

The micro-fabricated cores for the increasing and constant release profiles were placed
into PDMS wells where the pre-polymer solution without drug was poured and
polymerized under the UV-light. The three tablets for each geometry were placed in 5
mL PBS at pH=7.4 separately before being placed on a shaker which was set at 37°C
with shaking rate of 120 rpm. Almost every hour, 750 µl of each PBS solution was
withdrawn, transferred into three wells of a 96-well plate (each well contained 250 µl),
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and analyzed using a micro-plate reader (Asys UVM 340) instrument. The concentration of
the model compound in a 250 µl sample was calculated using the absorbance measured by a
micro-plate reader (Asys UVM 340) instrument. The concentrations were calculated using the
concentration-absorption calibration curve that was obtained by measuring the
absorbance of different known concentration of acid orange 10 in the wavelength with
the maximum absorbance of UV light (475 nm) (Appendix D-1). The wavelength in
which the model compound (orange G) has the highest absorption of UV-light was
identified by finding the maximum absorbance of acid orange 10 in solutions with known
concentrations shown in Appendix D-1. For the UV microplate reader device, the
absorbance-concentration relation was calculated as shown in Equation 4-1 where A is
the absorbance of the UV light by the model compound and C is the concentration of the
model compound in the sample. The absorbance is linearly related to the concentration.
The slope (α in Equation 4-1) was calculated for the micro-plate reader to be 27.13 by
fitting a linear line to absorbance-concentration data.
𝐴=𝛼𝐶

(4-1)

The absorbance of each sample was measured using the UV-plate reader, and the
concentration of the model compound in the sample was calculated using the Equation41. An equivalent amount of the fresh PBS (750 µl) was added after withdrawing the same
amount of solution. After collecting the concentration data of the model compound at
certain time intervals, the fractional release (Equation 4-2) and the release rates
(Equation4-3) of the model compound from each tablet were calculated. In Equation 4-2,
𝑀0 is the initial amount of the dye dispersed in the tablet which is known, 𝐶𝑖 is the
concentration of the model compound calculated for the 𝑖𝑡ℎ sample at time 𝑡, 𝑉𝑡 is the
total volume of the sample (e.g., 5mL in this study), and 𝑉𝑖 is the withdrawn sample
volume (250 µl per well or 750 µl per sample), and 𝐹𝑖 % is the fractional released
percentage of the dye.

𝐹𝑖 % =

𝐶𝑖 × 𝑉𝑡 + ∑𝑖−1
1 𝐶𝑗 𝑉𝑖
× 100
𝑀0

(4-2)
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In Equation 4-3, 𝑅𝑖 is the release rate of the model compound at time 𝑡 for the 𝑖𝑡ℎ sample,
and 𝑇𝑖 is the time at which the 𝑖𝑡ℎ sample was withdrawn.
𝑅𝑖 =

4.1.9

(𝐹𝑖 − 𝐹𝑖−1 ) × 𝑀0
𝑇𝑖 − 𝑇𝑖−1

(4-3)

Modified Tablet Designs to Increase the Loading Capacity

The tablet designs were modified to improve the capacity of the tablet for containing
higher quantities of therapeutics. One arm, two-arm, and four-arm designs for the core of
the tablets were devised to make use of extra spaces in the shell of cylindrical tablets. In
the modified designs, instead of using only the axial direction for releasing the dye, the
radial directions were used as well by loading the dye in two-arm and four-arm tablet
designs. Figure 4-7 A to C shows the schematic illustrations of the one-, two-, and fourarm tablet designs in front view, respectively. Although in the one-arm design, the core is
closest to the top of the tablet (same as the tablet designs described so far), in the two and
four-arm designs, the core is as close to the right, left, and bottom of the tablet as to the
top side. It means the water could access the dye from one, two, and four sides for the
tablets shown in Figure 4-7 A, B, and C, respectively.
As was shown in Figure 4-6C, similar to the increasing and constant designs, the
modified tablets are designed in a high-throughput connected pattern. The tablet cores
were printed as photo-masks and were fabricated using the high-throughput microfabrication method previously discussed. Similar to what was described in section 4.1.7,
tablets’ shells were fabricated with the help of PDMS cylindrical wells. Three separated
tablets for each design were immersed in PBS solution for the release test using the same
procedure mentioned above. The concentration of the model compound was calculated
using the absorbance values measured by the micro-plate reader. The fractional
percentage model compound released and the release rates for these three modified
designs were calculated using Equation 4-2 and 4-3 and then compared to each other.
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Figure 4-7: Schematic representations of modified tablet design to improve the loading
capacity. Front view of A) one-arm tablet design. B) two-arm tablet design. C) four-arm tablet
design.

4.1.10

Automated Tablet Designs

After determining the tablet design and choosing the suitable polymers for the tablets, the
tablet geometry is usually designed using computer-aided design (CAD) or drawing
software. There are several variables that should be considered for designing polymeric
tablets. Most of these variables are dependent on the physicochemical properties of the
polymers which affect their degradation or erosion kinetics. Polymeric tablets are
typically designed by AutoCAD software after solving the complex mathematical
equations governing the drug release kinetics. Expert tablet designers use powerful tools
and software to calculate the dimensions and design the geometry of the tablet by
considering all the essential variables.
Automation of the tablet design process saves a considerable amount of time and money
in the manufacturing process of personalized tablets. It also allows physicians to rapidly
design a tablet-based on the desired release rate, without the need for an expert designer.
A few commercial software programs were recently introduced that helps non-expert
individuals design commercially-available tablets in a user-friendly platform. For
example, in silico tablet formulations can be developed and tested using the formulationcomputer aided design (F-CAD) software platform of CINCAP 3. Researchers have also
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used TabletCAD (Natoli Engineering Company), which is a simple web-based user
interface for designing tablets that can be directly linked to the manufacturing process4.
In the design, using the bio-erodible polymer simplifies the automation of the tablet
design. This is due to the decreased calculation complexity required for determining the
drug release profiles from these polymers. In this study, a graphical user interface (GUI)
was created using the Python programming language for rapid designing of the patientspecific erodible tablets via a user-friendly platform without the need for expert
designers. The required dosage (concentration) of the drug during the course of treatment,
i.e., the desired release profile of the drug, are determined based on the diagnosis of the
physicians (Figure 4-8A). The thickness of the tablet core (which is 600 µm, in this case)
and dimensions reduction rates of the polymers, measured in section 4.2.1, were entered
as inputs. The weight percentage of the drug dispersed in the polymer was also
determined in the visual indicator. The 2D tablet core was automatically designed using
the user interface program based on the inputs. (Figure 4-8B). The complete explanation
of this developed user interface and an example of automated core design for the pulsatile
release tablet is included in Appendix E-1.

Figure 4-8: Automation of tablet designs. A) The importance of the personalized medicine and
automated tablets design based on the patient’s physiological condition. "Doctor with Patient
Cartoon.svg from Wikimedia Commons by Videoplasty.com, CC-BY-SA 4.0". B) The graphical
user interface was created for designing patient-specific tablets with specific release rates.
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4.2

Results and Discussion

This section presents and discusses the results of the tablet characterization, highthroughput fabrication of the tablet design, adjustable release profiles obtained from
various tablet designs, and modified designs to improve the loading capacity of the
proposed controlled-release tablets.

4.2.1

Tablet Characterization: Height and Diameter Reduction
Rates

Several studies have shown that polyanhydrides predominantly undergo surface
erosion5,6. Researchers have connected the surface erosion mechanism to the linear mass
loss profile of polyanhydrides that results in a near zero-order drug release from these
polymers7,8. Most of these studies used polyanhydrides in the form of a slab (a thin layer
of polymer). Using the new type of polyanhydrides synthesized by thiol-ene
photopolymerization, a rectangular slab (2× 10 × 10 mm) made of PNA and PETMP
showed a linear mass loss profile. More complicated mass loss profiles were observed for
a cube made of the same polymer9. In section 3.2.2.8, the mass loss behavior of cylinders
and cubes made of the polymers was examined over time. Results showed that the mass
loss of these polymers closely followed the cubic and quadratic functions rather than a
linear profile. The non-linearity observed in the mass loss profile of the more complex
thiol-ene polyanhydride geometries (such as cubes and cylinder), does not contradict the
surface eroding behavior of the polymer. Surface erosion behavior is defined as the
quality to preserve the tablet structure during the erosion time. This unchanging structure
of tablets is attributed to a similar dimension reduction rates in all directions. In this
section, the diameter and height variations for each tablet were monitored and calculated
from the photos that were taken at specific time intervals (approximately once every
hour) after the induction period. The average of the measured diameters and heights from
triplicate experiments for each tablet were plotted over time.
Results indicate the linear behavior of the dimension reduction for cylindrical tablets as
shown in Figure 4-9A, B. As discussed in section 3.2.2.1, an increased ratio of EGDT to
PETMP in the thiol-ene polyanhydrides network results in higher erosion rates. The rates
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of the reduction for both diameter and height of all the tablets were calculated by finding
the slope of the linear curves fitted to the measured data. Table 4-1 summarizes the
results of the reduction rates for diameters and heights of these four tablets. The
dimension reduction profiles in Figure 4-8 show that the reduction of diameters and
heights for each tablet is linear. In addition, similar diameter and height reduction rates
are observed for tablets made of the same polymers. Having the same reduction rate in
different dimensions is a very crucial characteristic for a polymer because it increases the
polymer’s applications in CRSs. The adjustable release rates from the tablet designs rely
on similar reduction rates in different dimensions.
The linear behavior of the reduction rates (the calculated correlation coefficients R2 ≈1)
observed in both dimensions (shown in Figure 4-9 A, C), allowed calculating the
expected dimension reduction rate of the same polymer for a new cylindrical design.
Ideally, this expected reduction rate can be calculated by measuring the dimensions of the
tablet at least at two arbitrary time points during erosion and fitting a linear function to
dimension vs. time data. The slope of the dimension-time data represents the reduction
rate. This linear behavior of the reduction rates showed in this study eliminates the need
for monitoring tablet dimensions during the erosion time. For example, by having the
initial and final dimensions and the erosion time, the reduction rates can be easily
calculated and used in the tablet design for releasing the pre-determined patterns of drugs.
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Figure 4-9: Linear reduction profiles of A) Diameters of four cylindrical tablets. B) Heights of
four cylindrical tablets. Schematic illustrations of C) horizontal direction of a cylindrical tablet
monitored to measure the diameter reduction rates and D) vertical direction of a cylindrical tablet
monitored to measure the height reduction rates.
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Table 4-1: Diameter and height reduction rates measured for cylindrical tablets.

4.2.2

Micro-fabrication of Tablet Cores

The designs of tablet cores, previously shown in Figure 4-6, were printed as photo-masks
and the SU-8 master molds were fabricated through photolithography steps (Figure 4-10
A). The PDMS molds were successfully fabricated via a standard soft-lithography
process using the SU-8 master molds. The depth of the chambers on PDMS negative
molds was measured using a microscope (Nikon 334 Eclipse Ti-E). The measured depths
ranged from 298 µm to 301 µm for different molds that are very close to the designed
value (300 µm), showing the successful fabrication of PDMS negative molds.
The original PDMS layer and the one with the mirrored pattern were put on top of each
other to create 600 µm cavities between them (Figure 4-10 B). Typically, two PDMS
layers irreversibly bound to each other or a PDMS layer bonds to a glass slide using a
standard O2 plasma activation process to make a microfluidic network10–12. However, the
pattern can be destroyed by the formation of an irreversible seal between the PDMS mold
and a glass slide

13

. Besides, in this study, there was a desire to access the features and

remove the dye-loaded polymer solution once it is cured in the network. Therefore, to
seal the channels and at the same time prevent the leakage of the fluid, at first, small
clamps were used to squeeze the two layers together as shown in Figure 4-10 C.
However, leakage of the polymer solution from the microfluidic channels was observed
using the clamps. Alternatively, two rigid PMMA sheets were utilized to sandwich the
PDMS layers. Screws and nuts were used to apply uniform force and to secure the
alignment. This platform was designed and fabricated for creating the tablet cores. The
successful injection of the pre-polymer solution containing the model compound via
inlet/outlet ports is shown in Figure 4-10 D.
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Figure 4-10: Development of the PDMS microfluidic network for creating the tablet core. A)
SU-8 master mold fabricated to make PDMS replica molds B) Putting two PDMS layers with the
mirror patterns on top of each other to create microfluidic cavities with 600 µm depth in between.
C) Using clamps for squeezing two PDMS layers for the elimination of the potential leakage. D)
Using two PMMA sheets to apply uniform forces on PDMS layers using uniformly distributed
screws.

4.2.3

PDMS Wells for Fabrication of Tablet Shells

To create the tablet shell, PDMS wells were successfully fabricated using 3D printed
master molds. Firstly, cubic wells were designed in a way that the distance between every
two adjacent cubes was the same as the distance between the two adjacent microfabricated tablet cores. The dye-loaded tablet cores were placed at the center of the wells
at a certain height (as explained in section 4.1.7) using external aligners. Two aligners
were used to hold the fabricated dye-containing part at the specific XYZ position. Figure
4-11A shows the printed cubic wells, the PDMS negative molds, and the three cubic
surface eroding tablets created in the cubic PDMS wells.
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Figure 4-11B shows an alternative design for the cubic wells’ in AutoCAD in which two
aligners were added at both ends of the 3D printed object. Two aligners were designed
with certain heights and a notch on them where the micro-fabricated tablet cores hang to
ensure the right XYZ position. These two aligners facilitate the correct placement of the
fabricated dye-containing part in the right location inside the well, without the need for
external aligners. All the tablet shell designs were changed to cylindrical objects (Figure
4-11C) since tablets with cubic shapes have sharp corners that are inconvenient to
swallow when used as oral tablets. The final optimized design was the cylindrical wells
with two aligners in both sides and two more aligners between every two adjacent wells
(Figure 4-11D). Aligners between wells were added to prevent the micro-fabricated part
from bending or collapsing due to the gravity.
The resolution of the method used for fabrication of the tablet core is of higher
importance than that of the tablet shell. The geometries of the μm-sized tablet cores
determine the release profile of the model compound and are also more complex than the
geometries of the mm-sized PDMS wells that form the tablet shell. However, this design
benefits from a higher resolution technique for producing PDMS wells (DLP 3D
printing), that is also capable of printing various geometries with sharp corners or
curvatures including cubes, cylinders, and spheres which are the common form of tablets
in the pharmaceutical industry. Higher surface quality of the tablet shells also ensures
more precise control over the erosion rate of the tablet in the novel design proposed in
this study. Lithography-based 3D printers (SLA and DLP) can create objects with more
complex designs at a higher speed and higher resolutions compared to the other
commercially available 3D printers such as FDM machines. SLA utilizes lasers to cure
the photo-curable solution point by point, while DLP uses a digital projector to cast and
cure an entire slice of objects14. In this study, a DLP 3D printer (PICO2, ASIGA) was
used to fabricate the master molds because of its fast and high-resolution manufacturing
process compared to the SLA counterparts. The limitation of the lithography-based 3D
printers is the limited number of the available UV-curable resins. Clear 2500T resin was
used after evaluating its thermal stability in an oven for 2 hours at 80 °C, which is the
same thermal condition for curing the PDMS on top of the printed master molds.
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Figure 4-11: Development of PDMS wells fabricated using the 3D printed master molds. A)
Cubic 3D printed master mold, PDMS cubic wells created using the master mold, and three
surface eroding polymers in a cubic shape fabricated using the PDMS mold. B) The new version
of the cubic well design with two aligners in both ends of the mold and the printed master mold.
C) Modified cylindrical wells design and the printed object. D) Final optimized cylindrical wells
design with four aligners to hold the tablet core.
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4.2.4

High-throughput Fabrication of Core-Shell Tablets

The cores and shells of the tablets were fabricated using the developed platform
described in section 4.1.74.1.6 for high-throughput manufacturing of the tablets. As an
example, the results of the high-throughput fabrication of the increasing release profile
tablets are shown in this section. Figure 4-12A shows the final device, developed for
fabricating the dye-loaded cores of the tablets. Figure 4-12 shows three tablet cores for
the increasing release profile that were fabricated and peeled off from the μm-sized
PDMS mold. The cross-linked dye-loaded features were set in place using the notch
aligners embedded in the PDMS wells that were created using the 3D printed master
molds (Figure 4-12B). Empty spaces in the wells were filled by the same surface eroding
polymer without the model compound. All three wells were then exposed to the UVlight, and the final connected tablets were peeled off from the PDMS wells as shown in
Figure 4-12C. These connected tablets were simply separated to obtain three individual
tablets for the increasing release profile (Figure 4-12D).

Figure 4-12: High-throughput fabrication of the increasing release profile core-shell tablets. A)
High-throughput platform to create the micrometer-sized tablet cores. B) Locating the cured
micro-fabricated tablet cores on PDMS wells to create the tablets’ shells. C) Three connected
core-shell tablets peeled off from the PDMS wells. D) Three separated increasing release profile
tablets.
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4.2.5

Tablets with Adjustable Release Profiles

The proposed tablet design in this study was tested at first for the constant release profile.
The constant release profile tablets were designed such that the surface area of the tablet
core from the top along its height was constant (Figure 4-13A). Figure 4-13B shows the
constant release profile core-shell tablet in PBS solution after the first half of the core is
eroded. The concentration of the model compound in the sample was measured
approximately once every hour and the fractional cumulative release of the model
compound was calculated and plotted over time (Figure 4-13C). Results show the linear
fractional release of the model compound. On the top left on the graph in Figure 4-13C,
the release rate of the model compound is plotted. The release rate is not changing over
time which agrees with the pre-determined constant release profile intended by the tablet
design.
To demonstrate the versatility of the tablet design, a different core-shell tablet was
designed and fabricated. The core was fabricated for a decreasing and then increasing
release profile of the model compound, as shown in Figure 4-14A. The surface area of
the tablet core from the top along its height is decreasing and then increasing. Figure 414C shows the fabricated core-shell tablet for decreasing-increasing release profile
(Figure 4-14B) in PBS solution after the first half of the erosion period. The fractional
cumulative release of the model compound was calculated and plotted (Figure 4-14D)
over time. The fractional release of the model compound shows two distinct sections, one
during the erosion of the decreasing part and the other happens during the erosion of the
increasing part. The data for these two parts were fitted to two quadratic models using
MATLAB MathWorks software. On the top left on the graph in Figure 4-14 D, the
release rates of the model compound were plotted which show a decreasing and then an
increasing release rate over time.
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Figure 4-13: Constant release profile of a core-shell tablet. A) The schematic representative of
the tablet core with the constant surface area from the top along its height and the position of the
tablet core are shown in the tablet front view. B) The fabricated constant release profile core-shell
tablet in PBS while it is eroding. C) The linear fractional drug release after the induction period

and the constant drug release rate on the top left side.

Release rates calculated for the constant and the decreasing-increasing release profile
core-shell tablets showed the feasibility of tuning the release pattern of the model
compound from the polymer using the proposed core-shell tablet design. The release
profile patterns were only dependent on the tablet’s core geometry, particularly the
variations in its surface area from the top along its height, as well as the location of the
tablet core inside the shell. The linear reduction rates of the erodible tablets’ dimensions
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(calculated in section 4.2.1), make it possible to estimate the release profiles of the drugs
from the tablets. Compared to other studies conducted on obtaining desired release
profiles from polymeric tablets15–17, the presented method is more straightforward and
does not require the complex modeling and/or solving of the complicated equations for
designing tablets with adjustable release profiles.

Figure 4-14: The decreasing-increasing release profile core-shell tablet. A) The schematic
representative of the tablet core with decreasing and then increasing surface area from the top
along its height and the location of the tablet core shown in the front view. B) The fabricated
decreasing-increasing tablet core C) The fabricated decreasing-increasing release profile coreshell tablet in PBS while it is eroding. D) The fractional model compound release after the
induction period and the decreasing-increasing release rates on the top left side.
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4.2.6

Modified Tablet designs towards Increasing the Loading
Capacity

The drug-loading capacity of a polymeric delivery system is the total amount of the drug
that can be loaded in the system and depends on the polymer, drug, fabrication method,
and the design of the DDS. As discussed before in section 3.2.2.6, in the tablet design, a
higher intensity UV-light source was required to cross-link the polymers containing
higher amounts of the model compound (or any other therapeutics). The high-intensity
UV-light transfers very high energy that may damage to therapeutics loaded in the
polymer. By modifying the tablet design and utilizing the extra space in the shell of the
tablet, higher amounts of the model compound can be loaded into the tablets without
increasing the total volumes of the tablets.
The height and the diameter reduction rates for polymers used in this study were
measured before in section 4.2.1 and results showed the similarity of the reduction rates.
One-arm, two-arm, and four-arm core-shell tablets were fabricated (
Figure 4-15A) using the high-throughput platform. The same weight percentage of the
model compound was added to these three tablet designs so that the total initial amount
of the dye loaded in the two-arm and four-arm tablets was two and four times higher than
the one-arm loaded dye, respectively. The cumulative release of the model compound
from all three tablets was calculated and the mean values from triplicate experiments
were plotted as shown in Figure 4-15B. Linear curves were fitted to data and slopes were
calculated, showing the constant release rates as expected (considering the tablet core
designs).
Figure 4-15C, D, and E show the tablets fabricated for constant release profiles while
they are eroding in PBS. The cumulative release of the model compound over time was
linear for all three fabricated tablets which acted as another indicator of obtaining a
constant release profile. Slopes of the linear lines were calculated to show the constant
release rates reported in
Figure 4-15B. The release rate of the four-arm tablet was almost four times higher than
the release rate of the one-arm tablet and the slope of the linear cumulative release of the
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two-arm tablet showed an almost twofold increase when compared to the one-arm tablet.
These findings also imply that using the four-arm design, it was possible to load (and
release) the same amount of model compound at almost four-times lower weight
percentage compared to the one-arm tablet. Consequently, the intensity of the UV-light
source required for curing the photocrosslinkable polymeric tablet cores will be reduced
which lowers the chances of damages to loaded drugs. Moreover, the results of this
experiment showed that more amount of the drug could be released using other sides of
the tablet as well as the top side, while preserving the desired release profile.
Researchers have studied the elevation of the loading capacity of controlled DDSs by
changing the polymer compositions18. Various fabrication techniques such as hot-melt
extrusion (HME) and injection molding (IM) were also used to increase the loading
capacity of the polymeric tablets19–21. In this study, using the modified tablet designs
which utilize more dimensions of the tablet for releasing the therapeutics, the loading
capacity of the designed tablets was increased by approximately four times.
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Figure 4-15: Modified core-shell tablet designs to increase the loading capacity of the delivery
system. A) Three core-shell tablets, fabricated for constant release profile with one-arm, two-arm,
and four-arm cores from left to right, respectively. B) The cumulative amount of the model
compound release after the induction period and linear fitted curve to the one-arm (the blue line),
two-arm (the green line), and four-arm (the red line) release data. The slopes are showing the
constant release rates in mg/hr. The core-shell tablets fabricated for constant release profiles
while eroding in PBS for C) one-arm, D) two-arm, E) and four-arm tablets.
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Chapter 5
Conclusions and Future Directions

5

In this thesis, the mass loss profiles of the thiol-ene polyanhydrides were
comprehensively studied, before utilizing them in the fabrication of tablets that were
designed to obtain adjustable release profiles. A high-throughput platform for
manufacturing the tablets is also presented. This chapter summarizes and highlights the
relevance of the thesis and guides future works.

5.1
5.1.1

Conclusions
Chapter 3

The photocrosslinkable thiol-ene polyanhydrides were successfully synthesized as was
indicated by the close agreement between the FTIR spectra of the polymers (Appendix
A-2) with the previously reported FTIR results for the same polymers. The glass
transition temperature values of the synthesized polymers using DSC were in agreement
with the values measured by DMA for the same polymers1.
The impact of the polymer composition on the polymer mass loss profiles (both the
induction and the erosion period) was studied by changing the initial mole ratios of the
cross-linkers (PETMP to EGDT). Although changing the polymer compositions did not
affect the induction period, an increased initial mole ratio of EGDT to PETMP resulted in
a shorter total erosion time (Figure 3-3). The reasons behind the changes in the erosion
times were investigated. The water contact angles of polymers were decreased for higher
EGDT to PETMP ratios. The lower values of the water contact angle indicate the lower
relative hydrophobicity of polymers, owing to their less cross-link density1 (Table 3-2).
Results of the PXRD, together with the results of the DSC experiments, illustrated the
lack of the crystallinity in the polymer structures (Figure 3-2 and Appendix A-4). The
amorphous domains of the polymers ensured that the crystallinity cannot be the reason
for the change in the erosion rate. Therefore, the difference in cross-link density, and
hence the hydrophobicity of polymers with different EGDT to PETMP ratios was found
to be the primary reason for the change in the erosion rates.
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The effect of the tablet geometry on mass loss profiles of the polyanhydrides was
examined by first comparing the mass loss profiles of small cylindrical tablets with the
larger ones made of same polymers. Similar induction periods and erosion patterns were
observed for the two tablet geometries (Figure 3-4), indicating that the thiol-ene
polyanhydrides maintain their surface erosion behavior even at very small dimensions
(e.g., 3mm which is in the range of our tablet cores’ size) similar to other types of
polyanhydrides2. Results show the potential of this type of polyanhydrides to be used in
small-size controlled DDSs, in particular for manufacturing mini-tablets for pediatric
patients. In another set of experiments, the impact of the surface area, volume, and SA/V
ratio on the erosion behavior of the tablets were examined (Figure 3-6 to 3-8). While the
induction period was not affected by these parameters, the mass loss percentage for a
polymer with a higher surface area and/or a lower volume was shown to be faster.
Polymers with the same SA/V ratios showed similar mass loss percentage rates despite
their dissimilar volumes and surface areas. The important role of the SA/V ratio in the
degradation behavior of tablets made of other biodegradable polymers has been shown
before3,4.
The impact of parameters such as the temperature, pH, and shaking rate of the PBS on the
mass loss profile of thiol-ene polyanhydrides was studied. A decrease in the induction
period (from 10 hours to 5 hours) was observed in the mass loss profile of the polymers
when the temperature was increased (25°C to 37°C). The erosion was considerably faster
at higher temperatures (Figure 3 4). The findings are in agreement with other studies
showing that the degradation of biodegradable polymers is accelerated at elevated
temperatures5–7. The induction periods and mass-loss rates were similar for polymers in
different pH, except for the one at pH=7.89, which showed a shorter induction period and
a faster mass loss rate (Figure 3 9). The increased mass loss rate of the polymer in the
alkaline solution is in agreement with results from other studies that showed an
acceleration in degradation of biodegradable polymers in more alkaline environments8,9.
The induction period and mass loss rate of polymers stayed similar at three shaking rates
(0, 60, 120 rpm), with a slightly slower erosion rate observed at a static condition (Figure
3-10). These findings indicated the non-significant effect of the shaking rate on mass loss
profile of this type of polyanhydrides which is similar to the behavior observed for
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another type of polyanhydride with the slightly slower erosion rate in the solution with a
lower shaking rate10. Mostly, adding hydrophilic compounds (such as the neutral form
of the lidocaine) to the polymers might decrease the cross-link density, which leads to a
faster mass loss. Although the dispersion of various amount of lidocaine (1, 2, and 3wt
%) in other cross-linked thiol-ene polyanhydrides caused slightly faster mass loss11,
dispersion of the 1 wt% model compound (acid orange 10) in the present polyanhydrides
did not make a difference in the mass-loss rates of the tablets (Figure 3-11).
The feasibility of eliminating the undesirable induction period (lag time) of thiol-ene
polyanhydrides was studied by pre eroding the polymers in PBS. After pre-erosion, i.e.
removing the tablets from PBS after the duration of the induction period and keeping
them in vacuum for 10 hours, when placed back in PBS polymers started eroding with a
similar mass loss rate without any second induction period (Figure 3-12). Elimination of
the lag time for a different polyanhydride (PCPM) by pre-erosion process has been
reported12. The successful elimination of the pre-erosion can be attributed to a decrease in
the hydrophobicity of the polymer surface caused by the hydrolysis that occurs when the
tablet is in contact with PBS in the pre-erosion period. Overall, temperature was the only
parameter that could affect the induction period substantially. The mass-loss rate,
however, was influenced by most of the parameters studied, including the polymer
composition and geometry as well as the temperature, pH, and shaking rate of the PBS
solution during the in vitro experiments.
Chapter 3 also documented data on the mass loss behavior of the cylindrical and cuboid
thiol-ene polyanhydrides by fitting their experimental mass loss data to linear, quadratic,
and cubic polynomials. Even though a linear mass loss profile is commonly reported for
surface eroding polymers2,13, the mass loss data of the present polymers more closely
followed the cubic and quadratic functions (Figure 3-13 and Table 3-3). The geometry of
the tablets is the reason behind this non-linear behavior of the mass loss data. Polymers in
the form of a slab show a linear mass loss while cubes or cylinders made of the same
polymer show more complicated patterns. The release kinetic models fitting was also
conducted to further investigate the mass loss profiles of the polymers. With the highest
R2 and the lowest RMSE, the Hopfenberg and Hixson-Crowell models best fitted to the
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cylindrical and cubic systems’ mass loss data (Table 3-4 and 3-5). These best-fitted
models describe the erosion mechanism of the systems rather than the diffusion
mechanisms that govern the other kinetic models used for data fitting.

5.1.2

Chapter 4

The surface erosion behavior of the photocrosslinkable polyanhydride was studied in
chapter 3 and results demonstrated that it is an appropriate candidate to be used for
fabricating drug-loaded tablets. Chapter 4 presented a novel core-shell tablet design in
which the core is made of a surface eroding polymer loaded with a drug, while the same
polymer without any drug was used for the shell (Figure 4-1). The position of the tablet
core inside the shell is such that the core is closest to the top, and far enough from the
other sides, ensuring that the release of the drug happens only from the top surface of the
tablet. Accordingly, the release profile of the drug is only governed by the variations in
the surface area of the drug-loaded core along its height. This design relies on the surface
eroding behavior of the polymer to preserve the tablet structure and integrity during the
erosion, as well as the similarity of the erosion rate at all sides of the tablet.
The tablet design requires only one type of surface eroding polymer in contrast to other
designs that utilized multiple polymers in tablet fabrication. For example, PLA has been
used in the form of layers or containers for achieving delayed, sequential, pulsatile,
release profiles as well as designs with adjustable release profiles14–18. Using multiple
polymers for manufacturing the tablets increases the time and complexity of the
fabrication process. Besides, the interactions between different polymers used in a DDS
can change their properties, and hence their erosion behavior. If not accounted for, this
may result in erroneous estimations of the release profile of drug from the DDS.
Therefore, in addition to characterizing the erosion behavior of each of the polymers
separately before manufacturing the tablet, studies should be conducted on characterizing
the erosion behavior of each of the polymers from the multi-polymer DDS after it is
manufactured. In addition, some polymers used in the multi-polymer DDSs have slow
degradation rates, e.g. PLA that is usually utilized for fabricating containers can take
several months to degrade19,20. The tablet design developed in this thesis overcomes the
aforementioned issues by utilizing only one surface eroding polymer.
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The design for achieving adjustable release rates relies on the similarity of the dimension
reduction rate of different sides of the tablet, i.e. the independence of the dimension
reduction rate from the orientation of the tablet. The diameter and height reduction rates
of cylindrical tablets made of thiol-ene polyanhydrides were obtained from mass loss
experiments and were found to be linear and very close to each other (Figure 4-9). The
linearity of the dimension reduction rates allows for estimating the dimension reduction
rate of a new cylindrical design made from the same polymer, without the need for
monitoring the tablet dimensions during the entire erosion time.
High-throughput manufacturing is currently a challenge for producing advanced
controlled DDSs with adjustable release rates. Most of the studies reported the fabrication
of a single tablet in each experiment18,21–23, reducing the chances of their practical use in
clinical settings. Manufacturing each tablet can take a considerable amount of time, and
the reproducibility level is low. In this study, a platform for high-throughput
manufacturing of the core-shell tablets was developed to provide adjustable release
profiles.
Tablet cores were fabricated using a microfluidic network consisting of two PDMS layers
manufactured using conventional soft-lithography techniques. To prevent the leakage of
the pre-polymer solution from the microfluidic network, two rigid PMMA sheets were
used to sandwich the PDMS layers and to apply a uniform force through a screw/nut
configuration. The successful injection of the pre-polymer solution via the inlet/outlet
ports was achieved (Figure 4-10). To create the tablet shell, PDMS wells were
successfully fabricated using 3D printed master molds. Aligners were designed to ensure
the right positioning of the micro-fabricated tablet cores in the shell (Figure 4-11). Highresolution tablet shells were fabricated by using DLP 3D printing for producing PDMS
wells. DLP was chosen because it can create objects with more complex designs at a
higher speed and higher resolutions compared to the other commercially available 3D
printers such as FDM machines which are previously used for manufacturing tablets with
adjustable release profiles 18,21–23.
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Results of the release rates measurements of the tablets designed for constant and the
decreasing-increasing release profiles showed the feasibility of achieving tunable patterns
of release using the proposed core-shell tablet design (Figure 4-13 and 4-14). Compared
to other studies 26–28, the presented method provides a more straightforward translation of
the desired release profiles to the tablet design, owing to the linearity of the surface
erosion rate observed in these experiments, along with the core-shell tablet design. Unlike
other studies

26–28

, complex modeling and/or solving of the complicated equations for

designing tablets with adjustable release profiles was not required.
By modifying the tablet design and utilizing the extra space in the shell polymer, higher
amounts of the model compound was loaded into the tablets without increasing the total
volumes of the tablets (
Figure 4-15). The modified design reduces the chances of the UV-induced damage to
therapeutics loaded in the tablet. One arm, two-arm, and four-arm designs for the core of
the tablets were devised by using the radial directions for erosion. The two- and four-arm
tablets preserved the estimated release pattern. The release rate of the four-arm tablet was
almost four times higher than the release rate of the one-arm tablet and the slope of the
linear cumulative release of the two-arm tablet showed an almost twofold increase when
compared to the one-arm tablet. These findings demonstrated that using the four-arm
design, it is possible to load (and release) the same amount of the model compound at
approximately four-times lower weight percentage compared to the one-arm tablet. This,
in turn, decreases the required UV-light energy for cross-linking the tablet cores and
hence reducing the chances of the damage to the loaded drugs. Other groups have studied
elevation of the loading capacity of controlled DDSs by changing the polymer
compositions29. Various fabrication techniques such as HME and IM were also used to
increase the loading capacity of the polymeric tablets30–32. In this study, using the
modified tablet designs, the loading capacity of the tablets was increased by
approximately four times, in a straightforward fashion.
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5.2

Future Directions

To further advance this study, the mass loss measurements can be conducted in PBS
solutions with changing pHs over time33 to mimic the conditions that a solid oral dosage
form would experience through the GI tract. In this regard, additional mass loss
experiments that are conducted in more physiologically relevant environments can help
provide more accurate predictions of the in vitro and ultimately in vivo erosion behavior
of these polymers. The release profile studies also need to be conducted for the tablet
loaded with an actual drug instead of a model compound.
To reduce the tablet manufacturing time, automation of some steps involved in the
fabrication of the tablets is recommended. A graphical user interface was developed that
automatically designs the tablets based on the information provided on the desired release
pattern (Appendix E-1). Although a pulsatile release profile was shown as a proof of
concept, other desired release profiles can be input to this user-friendly platform that
outputs the corresponding tablet design. The output of this program can then be utilized
for high-throughput fabrication of the tablets with the desired release profiles.
It is noteworthy that the simultaneous fabrication of three tablets (with either constant or
decreasing-increasing release profiles) was presented to demonstrate the potential of the
proposed method for large-scale production. Testing a design that includes a higher
number of simultaneously fabricated tablets is important to further validate the feasibility
of the proposed method for mass production. In addition, the design for achieving
adjustable release profiles should be used and tested for achieving other clinically
relevant and in-demand release profiles. Lastly, to improve the efficiency of the presented
delivery system and to further increase the drug loading capacity, other sides of the tablet
shell can also be utilized for drug release. A new modified design, together with a
modified fabrication technique is required to realize this goal.
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Appendices
Appendix A: Polymer prepration and characterization.

Appendix A-1: Thiol-Ene polymerization process for synthesizing: A) a linear network made of
PNA and EGDT. Reproduced from Ref

1

with permission. B) A cross-linked network made of

thiol-ene reaction of PNA and PETMP and the following degradation via hydrolysis. One or both
of these networks exist in the final polymer structure used in this study. Reproduced from Ref
with permission.

2
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Appendix A-2: ATR-FTIR spectra of A) PNA: PETMP = 1:1 shows the dual peaks of
anhydrides and the absence of thiol and vinyl functional groups’ peaks similar to Ref 3. B) The
same peaks for other synthesized polyanhydrides with different initial mole ratios of monomers.
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Appendix A-3: TGA traces for four polyanhydrides to check their decomposition temperatures
before doing the DSC experiments. Initial mole ratios of monomers used in samples were PNA:
PETMP: EGDT= A) 100:100:0. B) 100:75:25. C) 100:50:50. D) and 100:25:75. The
decomposition temperatures were seen at 329 °C, 328 °C, 324 °C, and 317 °C respectively.
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Appendix A-4: DSC of four different polymers with initial mole ratios of PNA: PETMP:
EGDT equal to: A) 100:100:0. B) 100:75:25. C) 100:50:50. D) 100:25:75.Tg were specified from
the second cycle of heat/cool steps and -25.1°C, -36.6°C, -48.9°C, and -55.8°C respectively.
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Appendix B: Mass loss data fitting.

Appendix B-1: Fitting mass loss data for cylindrical polymers. The linear, quadratic, and cubic
fitting curves and the R2 is written in graphs.
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Appendix B-2: Fitting mass loss data for cuboid polymers. The linear, quadratic, and cubic
fitting curves and the R2 is written in graphs.
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Appendix C: Release kinetic models fitting.

Appendix C-1: Fitting mass loss data to the zero-order kinetic model for cylindrical and cuboid
polymers.
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Appendix C-2: Fitting mass loss data to the First-order kinetic model for cylindrical and cuboid
polymers.
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Appendix C-3: Fitting mass loss data to the Higuchi kinetic model for cylindrical and cuboid
polymers.
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Appendix C-4: Fitting mass loss data to the Korsmeyer-Peppas kinetic model for cylindrical
and cuboid polymers.
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Appendix C-5: Fitting mass loss data to the Hixson-Crowell kinetic model for cylindrical and
cuboid polymers.
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Appendix D: Model compound (Orange G) absorbance-concentration calibration curve.

Appendix D-1: Calculation of the model compound (orange G) concentration. A) Finding the
wavelength that has the maximum absorbance intensity for OG solutions with known
concentrations. B) Concentration-absorbance calibration curve for OG at 475nm (maximum
absorbance) for the micro-plate reader.
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Appendix E: Automated Tablet design
The use of bio-erodible polymers simplifies the automation of the tablet design. This is
due to the decreased calculation complexity required for determining the drug release
profiles from these polymers. In this study, a graphical user interface (GUI) was created
using the Python programming language for automatically designing the patient-specific
erodible tablets via a user-friendly platform without the need for an expert designer. The
required dosage (concentration) of the drug during the course of treatment, i.e., the
desired release profile of drugs, is determined based on the diagnosis of the physicians
(Appendix E-1A). The thickness of the tablet core (which is 600 µm, in this case) and
reduction rates of the polymers which were measured in section 4.2.1 were entered as
inputs. The weight percentage of the drug dispersed in the polymer was also determined
in the visual indicator (Appendix E-1B). The 2D design of the tablet core is automatically
generated based on the desired release profile that was input to the user interface
program. (Appendix E-1D).
For instance, we assume a pulsatile release profile with three peaks over the treatment
time is requested by the user (the physician). In the tablet design, the drug release profile
is only dependent on the surface area of the tablet core from the top surface along its
height. Accordingly, the code calculates the height of the tablet core based on the userdefined inputs such as the total release time, and the polymer- and design-specific
variables (e.g. the linear reduction rates of polymers and the amount of drug can be
dispersed in the polymer). After plotting the 2D tablet core design, the cumulative drug
release is calculated and plotted (Figure 4-9C). Finally, the 3D tablet designs are created
in the code by adding the third dimension to the 2D pattern. This thickness is an input to
the program (Appendix E-1E).
The 2D tablet core design provided by the user interface program is transferred to the
AutoCAD software and is attached to the previously designed connected network
(Appendix E-1F, G). The automation process for designing the tablet core was
successfully conducted for a pulsatile release profile. The inputs required in this GUI can
either be obtained from the previously conducted experiments or from the results of a
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modeling study. This automation process eliminates the need for manual calculation and
design for each patient.

Appendix E-1: Automation of the tablet designs. A) Importance of the personalized medicine
and automated designing tablets based on the patient’s physiological conditions. "Doctor with
Patient Cartoon.svg from Wikimedia Commons by Videoplasty.com, CC-BY-SA 4.0". B) The
graphical user interface for designing the patient-specific tablets with specific release rates. C)
Cumulative drug release calculated by the program. D) The 2D tablet core designed using the
GUI. E) 3D tablet designed using the GUI. F) Transferred 2D tablet core designs to AutoCAD.
G) Attachment of the tablet core designs to the connecting network to create the high-throughput
tablet core designs.
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